

40 Rec'd PCT/PTO 0 2 OCT 2000

FORM-PTO-1390  
(Rev. 10-96)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

003300-685

U.S. APPLICATION NO. (If known, enter 37 CFR 1.5)

09/647544

INTERNATIONAL APPLICATION NO.  
PCT/SE99/00544INTERNATIONAL FILING DATE  
31 March 1999PRIORITY DATE CLAIMED  
2 April 1998 and 28 January 1999

## TITLE OF INVENTION

AN INTEGRIN HETERODIMER AND A SUBUNIT THEREOF

APPLICANT(S) FOR DO/EO/US

EVY LUNDGREN-ÅKERLUND

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

It is contemplated that this Application be prosecuted while using Claims 1 to 134 that were presented on May 29, 2000 during the international phase of prosecution as amended in the Preliminary Amendment filed herewith.

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
  2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
  3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay prosecution until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).
  4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
  5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
    - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☒ has been transmitted by the International Bureau.
    - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
  6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
  7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
    - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
    - b. ☐ have been transmitted by the International Bureau.
    - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
    - d. ☐ have not been made and will not be made.
  8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
  9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (signed Declaration will follow)
  10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
- Items 11. to 16. below concern other document(s) or information included:**
11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
  12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
  13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
  14. ☐ A substitute specification.
  15. ☐ A change of power of attorney and/or address letter.
  16. ☒ Other items or information:

Copies of Swedish Application No. 9801164-6, filed 2 April 1998 and Swedish Application No. 9900319-6, filed 28 January 1999 were submitted during the international phase of prosecution. Thus, the claim for priority has been substantiated.

This Application qualifies for small entity status.



(09/99)

U.S. APPLICATION NO. (if known) <b>09/647544</b>		INTERNATIONAL APPLICATION NO. PCT/SE99/00544		ATTORNEY'S DOCKET NUMBER 003300-685	
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	PTO USE ONLY
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO ..... \$860.00 (970) International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... \$690.00 (956) No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$710.00 (958) Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to U.S. PATENT AND TRADEMARK OFFICE International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$100.00 (962)					
<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>\$ 1,000.00</b>	
Surcharge of \$130.00 (154) for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).				20 <input type="checkbox"/> 30 <input type="checkbox"/> \$ --	
Claims	Number Filed	Number Extra	Rate		
Total Claims	134 -20 =	114	X\$18.00 (966)	\$	2,052.00
Independent Claims	38 -3 =	35	X\$80.00 (964)	\$	2,800.00
Multiple dependent claim(s) (if applicable)			+ \$270.00 (968)	\$	--
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 5,852.00</b>	
Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$ 2,926.00	
<b>SUBTOTAL =</b>				<b>\$ 2,926.00</b>	
Processing fee of \$130.00 (156) for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(f)).				20 <input type="checkbox"/> 30 <input type="checkbox"/> \$ --	
<b>TOTAL NATIONAL FEE =</b>				<b>\$ 2,926.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +				\$ --	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$ 2,926.00</b>	
				Amount to be:	
				refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>2,926.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Benton S. Duffett, Jr. BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404					
22,030 REGISTRATION NUMBER					

FORM-PTO-1390 (Rev. 10-98)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER  <b>003300-685</b>  U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) <b>09/647544</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES          DESIGNATED/ELECTED OFFICE (DO/EO/US)          CONCERNING A FILING UNDER 35 U.S.C. 371</b>		
INTERNATIONAL APPLICATION NO. <b>PCT/SE99/00544</b>	INTERNATIONAL FILING DATE <b>31 March 1999</b>	PRIORITY DATE CLAIMED <b>2 April 1998 and 28 January 1999</b>
TITLE OF INVENTION <b>AN INTEGRIN HETERODIMER AND A SUBUNIT THEREOF</b>		
APPLICANT(S) FOR DO/EO/US <b>EVY LUNDGREN-ÅKERLUND</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: It is contemplated that this Application be prosecuted while using Claims 1 to 134 that were presented on May 29, 2000 during the international phase of prosecution as amended in the Preliminary Amendment filed herewith.		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and the PCT Articles 22 and 39(1).</li> <li>4. <input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ol> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). (signed Declaration will follow)</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 11. to 16. below concern other document(s) or information included:		
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.  <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information:</li> </ol>		
Copies of Swedish Application No. 9801164-6, filed 2 April 1998 and Swedish Application No. 9900319-6, filed 28 January 1999 were submitted during the international phase of prosecution. Thus, the claim for priority has been substantiated.  This Application qualifies for small entity status.		

528 Red 6307710 02 OCT 2000

U.S. APPLICATION NO. (if known) 09/647544INTERNATIONAL APPLICATION NO.  
PCT/SE99/00544ATTORNEY'S DOCKET NUMBER  
003300-68517. ☒ The following fees are submitted:

CALCULATIONS

PFO USE ONLY

**Basic National Fee (37 CFR 1.492(a)(1)-(5)):**

Search Report has been prepared by the EPO or JPO ..... \$860.00 (970)

International preliminary examination fee paid to USPTO (37 CFR 1.482) ..... \$690.00 (956)

No international preliminary examination fee paid to USPTO (37 CFR 1.482)  
but international search fee paid to USPTO (37 CFR 1.445(a)(2)) ..... \$710.00 (958)Neither international preliminary examination fee (37 CFR 1.482) nor  
international search fee (37 CFR 1.445(a)(2)) paid to U.S. PATENT AND TRADEMARK OFFICEInternational preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(2)-(4) ..... \$100.00 (962)**ENTER APPROPRIATE BASIC FEE AMOUNT = \$ 1,000.00**Surcharge of \$130.00 (154) for furnishing the oath or declaration later than  
months from the earliest claimed priority date (37 CFR 1.492(e)).20 ☐ 30 ☐

\$ --

Claims	Number Filed	Number Extra	Rate		
Total Claims	134 -20 =	114	X\$18.00 (956)	\$ 2,052.00	
Independent Claims	38 -3 =	35	X\$80.00 (964)	\$ 2,800.00	
Multiple dependent claim(s) (if applicable)			+ \$270.00 (968)	\$ --	

**TOTAL OF ABOVE CALCULATIONS = \$ 5,852.00**Reduction for 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be  
filed. (Note 37 CFR 1.9, 1.27, 1.28). \$ 2,926.00**SUBTOTAL = \$ 2,926.00**Processing fee of \$130.00 (156) for furnishing the English translation later than  
months from the earliest claimed priority date (37 CFR 1.492(f)).20 ☐ 30 ☐

\$ --

**TOTAL NATIONAL FEE = \$ 2,926.00**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by  
an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 (581) per property +

\$ --

**TOTAL FEES ENCLOSED = \$ 2,926.00**

Amount to be:

refunded \$

charged \$

- a. ☒ A check in the amount of \$ 2,926.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 02-4800 in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4800. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Benton S. Duffett, Jr.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

SIGNATURE

Benton S. Duffett, Jr.

NAME

22,030

REGISTRATION NUMBER

Filed: October 2, 2000

09/647544

528 Rec'd PCT/PTO 02 OCT 2000

Patent  
Attorney's Docket No. 003300-685

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	BOX PCT
	)	Attention: DO/EO/US
EVY LUNDGREN-ÅKERLUND	)	
	)	
Application No.: Unassigned	)	Group Art Unit: Unassigned
	)	
Filed: October 2, 2000	)	Examiner: Unassigned
	)	
For: AN INTEGRIN HETERODIMER	)	
AND A SUBUNIT THEREOF	)	
	)	
	)	

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This application corresponds to International Application No. PCT/SE99/00544,  
filed March 31, 1999.

It is contemplated that this Application be prosecuted while using Claims 1 to 134  
that were submitted on May 29, 2000 during the international phase of prosecution as  
further amended herein.

**In the Abstract:**

Please add the Abstract of the Disclosure that is provided on a separate sheet.

In the Claims:

Claim 8, lines 1 and 2, delete "in any one of claims 6 and 7" and insert --claim 6--.

Claim 20, line 1, delete "or 19".

Claim 21, line 1, delete "or 19".

Claim 26, line 2, delete "any one of claims 22-25" and insert --claim 22--.

Claim 27, lines 2 and 3, delete "any one of claims 22-25" and insert --claim 22--.

Claim 28, line 3, delete "any one of claims 22-25" and insert --claim 22--.

Claim 38, lines 1 and 2, delete "any one of claims 31-37" and insert --claim 31--.

Claim 41, lines 1 and 2, delete "any one of claims 31-37" and insert --claim 31--.

Claim 42, lines 1 and 2, delete "any one of claims 31-37" and insert --claim 31--.

Claim 43, lines 1 and 2, delete "any one of claims 31-37" and insert --claim 31--.

Claim 44, lines 1 and 2, delete "any one of claims 31-37" and insert --claim 31--.

Claim 45, line 1, delete "any one of claims 31-37 and insert --claim 31--.

Claim 52, lines 1 and 2, delete "any one of claims 46-51" and insert --claim 46--.

Claim 53, lines 1 and 2, delete "any one of claims 46-51" and insert --claim 46--.

Claim 60, lines 1 and 2, delete "any one of claims 54-59" and insert --claim 54--.

Claim 72, lines 1 and 2, delete "any one of claims 64-71" and insert --claim 64--.

Claim 93, line 1, delete "any one of claims 86-92" and insert --claim 86--.

Claim 96, line 1, delete "any one of claims 86-92" and insert --claim 86--.

Claim 97, line 1, delete "any one of claims 86-92" and insert --claim 86--.

Claim 98, line 1, delete "any one of claims 86-92" and insert --claim 86--.

Claim 105, lines 1 and 2, delete "any one of claims 99-104" and insert --claim  
99--.

Claim 106, lines 1 and 2, delete "any one of claims 99-104" and insert --claim  
99--.

Claim 113, lines 1 and 2, delete "any one of claims 107-112" and insert --claim  
107--.

Claim 125, lines 1 and 2, delete "any one of claims 117-124" and insert --claim  
117--.

**REMARKS**

The present Amendment adds an Abstract of the Disclosure on a separate sheet and  
eliminates the use of multiple dependency.

The examination and allowance of the application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L. L. P.

By: Benton S. Duffett Jr.  
Benton S. Duffett, Jr.  
Registration No. 22,030

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: October 2, 2000



### Abstract of the Disclosure

A recombinant or isolated integrin heterodimer comprising a novel subunit  $\alpha 10$  in association with a subunit  $\beta$  is described. The  $\alpha 10$  integrin may be purified from bovine chondrocytes on a collagen-type-II affinity column. The integrin or the subunit  $\alpha 10$  can be used as marker or target of all types of cells, e.g. of chondrocytes, osteoblasts and fibroblasts. The integrin or subunit  $\alpha 10$  thereof can be used as marker or target in different physiological or therapeutic methods. They can also be used as active ingredients in pharmaceutical compositions and vaccines.

Attorney's Docket No. 003300-685

Applicant or Patentee: EVY LUNDGREN-ÅKERLUND

Application or Patent No.: \_\_\_\_\_

Filed or Issued: October 26, 2000For: AN INTEGRIN HETERODIMER AND A SUBUNIT THEREOF**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS  
(37 C.F.R. §§ 1.9(f) AND 1.27(c)) - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☒ the owner of the small business concern identified below;  
☐ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN CARTELA ABADDRESS OF CONCERN c/o Evy Lundgren-ÅkerlundTrollsjövägen 165, 237 33 Bjärred, Sweden

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. § 121.12, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under Sections 41(a) and 41(b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average, over the previous fiscal year of the concern, of the persons employed on a full-time, part-time, or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled  
An integrin heterodimer and a subunit thereof

by inventor(s) Evy Lundgren-Åkerlund  
described in

- ☐ the specification filed herewith  
☒ Application No. PCT/SE99/00544, filed 31 March 1999  
☐ Patent No. \_\_\_\_\_, issued \_\_\_\_\_

If the rights held by the above-identified small business concern are not exclusive, each individual, concern, or organization having rights to the invention is listed below,\* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 C.F.R. § 1.9(c), or by any concern that would not qualify as either a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern, or organization having rights to the invention averring to their status as small entities. (37 C.F.R. § 1.27.)

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ individual ☐ small business concern ☐ nonprofit organization

NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ individual ☐ small business concern ☐ nonprofit organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earlier of the issue fee and any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. § 1.28(b).)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code; and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING EVY LUNDGREN - ÅKERLUND

TITLE OF PERSON OTHER THAN OWNER MANAGING DIRECTOR

ADDRESS OF PERSON SIGNING Trollsjövägen 165

237 33 BJÄRRED, SWEDEN

SIGNATURE *Evvy Lundgren Åkerlund* DATE 2000-10-09

AN INTEGRIN HETERODIMER AND A SUBUNIT THEREOF

FIELD OF THE INVENTION

The present invention relates to a recombinant or isolated integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , the subunit  $\alpha 10$  thereof, homologues and fragments of said integrin and of said subunit  $\alpha 10$  having similar biological activity, processes of producing the same, polynucleotides and oligonucleotides encoding the same, vectors and cells comprising the same, binding entities binding specifically to the same, and the use of the same.

BACKGROUND OF THE INVENTION

The integrins are a large family of transmembrane glycoproteins that mediate cell-cell and cell-matrix interactions (1-5). All known members of this superfamily are non-covalently associated heterodimers composed of an  $\alpha$ - and a  $\beta$ -subunit. At present, 8  $\beta$ -subunits ( $\beta 1$ - $\beta 8$ ) (6) and 16  $\alpha$ -subunits ( $\alpha 1$ - $\alpha 9$ ,  $\alpha v$ ,  $\alpha M$ ,  $\alpha L$ ,  $\alpha X$ ,  $\alpha IIb$ ,  $\alpha E$  and  $\alpha D$ ) have been characterized (6-21), and these subunits associate to generate more than 20 different integrins. The  $\beta 1$ -subunit has been shown to associate with ten different  $\alpha$ -subunits,  $\alpha 1$ - $\alpha 9$  and  $\alpha v$ , and to mediate interactions with extracellular matrix proteins such as collagens, laminins and fibronectin. The major collagen binding integrins are  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  (22-25). The integrins  $\alpha 3\beta 1$  and  $\alpha 9\beta 1$  have also been reported to interact with collagen (26,27) although this interaction is not well understood (28). The extracellular N-terminal regions of the  $\alpha$  and  $\beta$  integrin subunits are important in the binding of ligands (29,30). The N-terminal region of the  $\alpha$ -subunits is composed of a seven-fold repeated sequence (12,31) containing FG and GAP consensus sequences. The repeats are predicted to fold into a  $\beta$ -propeller domain

(32) with the last three or four repeats containing putative divalent cation binding sites. The  $\alpha$ -integrin subunits  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha D$ ,  $\alpha E$ ,  $\alpha L$ ,  $\alpha M$  and  $\alpha X$  contain a ~200 amino acid inserted domain, the I-domain (A-domain), which shows similarity to sequences in von Willebrand factor, cartilage matrix protein and complement factors C2 and B (33,34). The I-domain is localized between the second and third FG-GAP repeats, it contains a metal ion-dependent adhesion site (MIDAS) and it is involved in binding of ligands (35-38).

Chondrocytes, the only type of cells in cartilage, express a number of different integrins including  $\alpha 1\beta 1$ ,  $\alpha 2\beta 1$ ,  $\alpha 3\beta 1$ ,  $\alpha 5\beta 1$ ,  $\alpha 6\beta 1$ ,  $\alpha v\beta 3$ , and  $\alpha v\beta 5$  (39-41). It has been shown that  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  mediate chondrocyte interactions with collagen type II (25) which is one of the major components in cartilage. It has also been shown that  $\alpha 2\beta 1$  is a receptor for the cartilage matrix protein chondroadherin (42).

## 20 SUMMARY OF THE INVENTION

The present invention relates to a novel collagen type II binding integrin, comprising a subunit  $\alpha 10$  in association with a subunit  $\beta$ , especially subunit  $\beta 1$ , but also other  $\beta$ -subunits may be contemplated. In preferred embodiments, this integrin has been isolated from human or bovine articular chondrocytes, and human chondrosarcoma cells.

The invention also encompasses integrin homologues of said integrin, isolated from other species, such as bovine integrin heterodimer comprising a subunit  $\alpha 10$  in association with a subunit  $\beta$ , preferably  $\beta 1$ , as well as homologues isolated from other types of human cells or from cells originating from other species.

The present invention relates in particular to a recombinant or isolated integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, and homologues and or fragments thereof having the

same biological activity.

The invention further relates to a process of producing a recombinant integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID

5 No. 2, or homologues or fragments thereof having similar biological activity, which process comprises the steps of

a) isolating a polynucleotide comprising a nucleotide sequence coding for a integrin subunit  $\alpha 10$ , or homologues or fragments thereof having similar biological

10 activity,  
b) constructing an expression vector comprising the isolated polynucleotide,

c) transforming a host cell with said expression vector,

15 d) culturing said transformed host cell in a culture medium under conditions suitable for expression of integrin subunit  $\alpha 10$ , or homologues or fragments thereof having similar biological activity, in said transformed host cell, and, optionally,

20 e) isolating the integrin subunit  $\alpha 10$ , or homologues or fragments thereof having the same biological activity, from said transformed host cell or said culture medium.

The integrin subunit  $\alpha 10$ , or homologues or fragments thereof having the same biological activity, can also be

25 provided by isolation from a cell in which they are naturally present.

The invention also relates to an isolated polynucleotide comprising a nucleotide coding for a integrin subunit  $\alpha 10$ , or homologues or fragments thereof having

30 similar biological activity, which polynucleotide comprises the nucleotide sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or parts thereof.

The invention further relates to an isolated polynucleotide or oligonucleotide which hybridises to a DNA

35 or RNA encoding an integrin subunit  $\alpha 10$ , having the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or homologues or fragments thereof, wherein said polyoligo-

nucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding the integrin subunit  $\alpha 1$ .

The invention relates in a further aspect to vectors comprising the above polynucleotides, and to cells containing said vectors and cells that have polynucleotides or oligonucleotides as shown in SEQ ID No. 1 or 2 integrated in their genome.

The invention also relates to binding entities having the capability of binding specifically to the integrin subunit  $\alpha 10$  or to homologues or fragments thereof, such as proteins, peptides, carbohydrates, lipids, natural ligands, polyclonal antibodies or monoclonal antibodies.

In a further aspect, the invention relates to a recombinant or isolated integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , in which the subunit  $\alpha 10$  comprises the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or homologues or fragments thereof having similar biological activity.

In a preferred embodiment thereof, the subunit  $\beta$  is  $\beta 1$ .

The invention also relates to a process of producing a recombinant integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , in which the subunit  $\alpha 10$  comprises the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, which process comprises the steps of

a) isolating one polynucleotide comprising a nucleotide sequence coding for a subunit  $\alpha 10$  of an integrin heterodimer and, optionally, another polynucleotide comprising a nucleotide sequence coding for a subunit  $\beta$  of an integrin heterodimer, or for homologues or fragments thereof having similar biological activity,

b) constructing an expression vector comprising said isolated polynucleotide coding for said subunit  $\alpha 10$  in combination with an expression vector comprising said isolated nucleotide coding for said subunit  $\beta$ ,

c) transforming a host cell with said expression vectors,

d) culturing said transformed host cell in a culture medium under conditions suitable for expression of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or homologues or fragments thereof similar biological activity, in said transformed host cell, and, optionally,

e) isolating the integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or homologues or fragments thereof having the same biological activity, from said transformed host cell or said culture medium.

The integrin heterodimer, or homologues or fragments thereof having similar biological activity, can also be provided by isolation from a cell in which they are naturally present.

The invention further relates to a cell containing a first vector, said first vector comprising a polynucleotide coding for a subunit  $\alpha 10$  of an integrin heterodimer, or for homologues or parts thereof having similar biological activity, which polynucleotide comprises the nucleotide sequence shown in SEQ ID No. 1 or SEQ ID No. 2 or parts thereof, and, optionally, a second vector, said second vector comprising a polynucleotide coding for a subunit  $\beta$  of an integrin heterodimer, or for homologues or fragments thereof.

In still another aspect, the invention relates to binding entities having the capability of binding specifically to the integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having similar biological activity, preferably wherein the subunit  $\beta$  is  $\beta 1$ . Preferred binding entities are proteins, peptides, carbohydrates, lipids, natural ligands, polyclonal antibodies and monoclonal antibodies.

In a further aspect, the invention relates to a fragment of the integrin subunit  $\alpha 10$ , which fragment is a peptide chosen from the group comprising peptides of



the cytoplasmic domain, the I-domain and the spliced domain.

In one embodiment, said fragment is a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ.

5 In another embodiment, said fragment comprises the amino acid sequence from about amino acid no. 952 to about amino acid no. 986 of SEQ ID No. 1.

In a further embodiment, said fragment comprises the amino acid sequence from about amino acid No. 140 to about amino acid No. 337 in SEQ ID No. 1.

Another embodiment of the invention relates to a polynucleotide or oligonucleotide coding for a fragment of the human integrin subunit  $\alpha 10$ . In one embodiment this polynucleotide or oligonucleotide codes for a fragment  
15 which is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain. In further embodiments the polynucleotide or oligonucleotide codes for the fragments defined above.

The invention also relates to binding entities having the capability of binding specifically to a fragment of the integrin subunit  $\alpha 10$  as defined above.

The invention also relates to a process of using an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin  
25 heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or a homologue or fragment of said integrin or subunit having similar biological activity, as a marker or target molecule of cells or tissues expressing said integrin subunit  $\alpha 10$ , which cells or tissues are of animal including human origin.

In an embodiment of this process the fragment is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain.

In further embodiments of said process the fragment is a peptide comprising the amino acid sequence  
35 KLGFFAHKKIPEEEKREEKLEQ, or a fragment comprising the amino acid sequence from about amino acid No. 952 to

about amino acid No. 986 of SEQ ID No. 1, or a fragment comprising the amino acid sequence from about amino acid no. 140 to about amino acid no. 337 of SEQ ID no. 1.

- The subunit  $\beta$  is preferably  $\beta 1$ . The cells are preferably chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

- Said process may be used during pathological conditions involving said subunit  $\alpha 10$ , such as pathological conditions comprising damage of cartilage, or comprising trauma, rheumatoid arthritis and osteoarthritis.

Said process may be used for detecting the formation of cartilage during embryonal development, or for detecting physiological or therapeutic reparation of cartilage.

- Said process may also be used for selection and analysis, or for sorting, isolating or purification of chondrocytes.

- A further embodiment of said process is a process for detecting regeneration of cartilage or chondrocytes during transplantation of cartilage or chondrocytes.

A still further embodiment of said process is a process for in vitro studies of differentiation of chondrocytes.

- The invention also comprises a process of using binding entities having the capability of binding specifically to an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having similar biological activity, as markers or target molecules of cells or tissues expressing said integrin subunit  $\alpha 10$ , which cells or tissues are of animal including human origin.

- The fragment in said process may be a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain. In preferred embodiments said fragment is a peptide comprising the

amino acid sequence KLGFFAHKKIPEEEKREEKLEQ, or a fragment comprising the amino acid sequence from about amino acid No. 952 to about amino acid No. 986 of SEQ ID No. 1, or a fragment comprising the amino acid sequence from about amino acid No. 140 to about amino acid no. 337 of SEQ ID No. 1.

The process may also be used for detecting the presence of an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or of an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or of homologues or fragments thereof having similar biological activity.

In a further embodiment said process is a process for determining the differentiation-state of cells during embryonic development, angiogenesis, or development of cancer.

In a still further embodiment this process is a process for detecting the presence of an integrin subunit  $\alpha 10$ , or of a homologue or fragment of said integrin subunit having similar biological activity, on cells, whereby a polynucleotide or oligonucleotide chosen from the group comprising a polynucleotide or oligonucleotide chosen from the nucleotide sequence shown in SEQ ID No. 1 is used as a marker under hybridisation conditions wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ . Said cells may be chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts. Said integrin fragment may be a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain, such as a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ, or a fragment comprising the amino acid sequence from about amino acid no. 952 to about amino acid no. 986 of SEQ ID No. 1, or a fragment comprising the amino acid sequence from about amino acid No. 140 to about amino acid no. 337 of SEQ ID No. 1.

In a still further embodiment the process is a process for determining the differentiation-state of cells during development, in pathological conditions, in tissue regeneration or in therapeutic and physiological reparation of cartilage. The pathological conditions may be any pathological conditions involving the integrin subunit  $\alpha 10$ , such as rheumatoid arthritis, osteoarthritis or cancer. The cells may be chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

The invention also relates to a process for determining the differentiation-state of cells during development, in pathological conditions, in tissue regeneration and in therapeutic and physiological reparation of cartilage, whereby a polynucleotide or oligonucleotide chosen from the nucleotide sequence shown in SEQ ID No. 1 is used as a marker under hybridisation conditions wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ . Embodiments of this aspect comprise a process, whereby said polynucleotide or oligonucleotide is a polynucleotide or oligonucleotide coding for a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain, such as a polynucleotide or oligonucleotide coding for a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ, or comprising the amino acid sequence from about amino acid No. 952 to about amino acid no. 986 of SEQ ID No. 1, or the amino acid sequence from about amino acid No. 140 to about amino acid No. 337 of SEQ ID No. 1. Said pathological conditions may be any pathological conditions involving the integrin subunit  $\alpha 10$ , such as rheumatoid arthritis, osteoarthritis or cancer, or atherosclerosis or inflammation. Said cells may be chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

In a further aspect the invention relates to a pharmaceutical composition comprising as an active ingredient a pharmaceutical agent or an antibody which is capable of using an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$  having similar biological activity, as a target molecule. An embodiment of said pharmaceutical composition is intended for use in stimulating, inhibiting or blocking the formation of cartilage, bone or blood vessels. A further embodiment comprises a pharmaceutical composition for use in preventing adhesion between tendon/ligaments and the surrounding tissue after infection, inflammation and after surgical intervention where adhesion impairs the function of the tissue.

The invention is also related to a vaccine comprising as an active ingredient an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$ , or DNA or RNA coding for said integrin subunit  $\alpha 10$ .

A further aspect of the invention is related to the use of the integrin subunit  $\alpha 10$  as defined above as a marker or target in transplantation of cartilage or chondrocytes.

A still further aspect of the invention is related to a method of using binding entities having the capability of binding specifically to an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having similar biological activity, for promoting adhesion of chondrocytes and/or osteoblasts to surfaces of implants to stimulate osseointegration.

The invention is also related to the use of an integrin subunit  $\alpha 10$  or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$  as a target for anti-

adhesive drugs or molecules in tendon, ligament, skeletal muscle or other tissues where adhesion impairs the function of the tissue.

The invention also relates to a method of stimulating, inhibiting or blocking the formation of cartilage or bone, comprising administration to a subject a suitable amount of a pharmaceutical agent or an antibody which is capable of using an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$  having similar biological activity, as a target molecule.

In another embodiment the invention is related to a method of preventing adhesion between tendon/ligaments and the surrounding tissue after infection, inflammation and after surgical intervention where adhesion impairs the function of the tissue, comprising administration to a subject a suitable amount of a pharmaceutical agent or an antibody which is capable of using a integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$  having similar biological activity, as a target molecule.

The invention also relates to a method of stimulating extracellular matrix synthesis and repair by activation or blockage of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or of the subunit  $\alpha 10$  thereof, or of a homologue or fragment of said integrin or subunit  $\alpha 10$  having similar biological activity.

In a further aspect the invention relates to a method of in vitro detecting the presence of integrin binding entities, comprising interaction of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit, with a sample, thereby causing said integrin, subunit  $\alpha 10$ , or homologue or fragment thereof having similar biological activity, to modulate

the binding to its natural ligand or other integrin binding proteins present in said sample.

- The invention also relates to a method of in vitro studying consequences of the interaction of a human
- 5 heterodimer integrin comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit, with an integrin binding entity and thereby initiate a cellular reaction. Said consequences may be measured as alterations in cellular functions.
- 10

- A still further aspect of the inventions relates to a method of using DNA or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof as a molecular target. In an embodiment of this aspect, a polynucleotide
- 15 or oligonucleotide hybridises to the DNA or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof, whereby said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ .

- 20 The invention also relates to a method of using a human heterodimer integrin comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit, or a DNA or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof, as a marker or target molecule during angiogenesis.
- 25

#### BRIEF DESCRIPTION OF THE FIGURES

- Fig.1 Affinity purification of the  $\alpha 10$  integrin subunit on collagen type II-Sepharose.
- 30 Fig. 2. Amino acid sequences of peptides from the bovine  $\alpha 10$  integrin subunit.
- Fig. 3a. Affinitypurification and immunoprecipitation of the integrin subunit  $\alpha 10$  from bovine chondrocytes.
- 35 Fig. 3b. Affinitypurification and immunoprecipitation of the integrin subunit  $\alpha 10$  from human chondrocytes.

Fig. 3c. Affinitypurification and immunoprecipitation of the integrin subunit  $\alpha 10$  from human chondrosarcoma cells.

Fig. 4. A 900 bp PCR-fragment corresponding to the  
5 bovine integrin subunit  $\alpha 10$

Fig. 5. Schematic map of the three overlapping  $\alpha 10$  clones.

Fig. 6. Nucleotide sequence and deduced amino acid sequence of the human  $\alpha 10$  integrin subunit.

10 Fig. 7. Northern blot of integrin  $\alpha 10$  mRNA.

Fig. 8 Immunoprecipitation of the  $\alpha 10$  integrin subunit from human chondrocytes using antibodies against the cytoplasmic domain of  $\alpha 10$  (a). Western blot of the  $\alpha 10$  associated  $\beta$ -chain (b).

15 Fig. 9. Immunostaining of  $\alpha 10$  integrin in human articular cartilage.

Fig. 10 Immunostaining of  $\alpha 10$  integrin in 3 day mouse limb cartilage.

20 Fig. 11. Immunostaining of  $\alpha 10$  integrin in 13.5 day mouse embryo.

Fig. 12. Hybridisation of  $\alpha 10$  mRNA in various human tissues.

25 Fig. 13 Immunostaining of fascia around tendon (a), skeletal muscle (b) and heart valves (c) in 3 day mouse limb.

Fig. 14. PCR fragments corresponding to  $\alpha 10$  integrin subunit from human chondrocytes, human endothelial cells, human fibroblasts and rat tendon.

30 Fig. 15. Partial genomic nucleotide sequence of the human integrin subunit  $\alpha 10$ .

Fig. 16. Upregulation of  $\alpha 10$  integrin subunit in chondrocytes cultured in alginate.

35 Fig. 17. Immunoprecipitation of the  $\alpha 10$  integrin subunit from human smooth muscle cells

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention demonstrate that human and



bovine chondrocytes express a novel, collagen type II-binding integrin in the  $\beta 1$ -family. An earlier study presented some evidence for that human chondrosarcoma cells also express this integrin (25). Immunoprecipitation experiments using antibodies against the integrin subunit  $\beta 1$  revealed that this novel  $\alpha$ -integrin subunit had an apparent molecular weight ( $M_r$ ) of approximately 160 kDa under reducing conditions, and was slightly larger than the  $\alpha 2$  integrin subunit. To isolate this  $\alpha$ -subunit collagen type II-binding proteins were affinity purified from bovine chondrocytes. The chondrocyte lysate was first applied to a fibronectin-Sepharose precolumn and the flow through was then applied to a collagen type II-Sepharose column. A protein with  $M_r$  of approximately 160 kD was specifically eluted with EDTA from the collagen column but not from the fibronectin column. The  $M_r$  of this protein corresponded with the  $M_r$  of the unidentified  $\beta 1$ -related integrin subunit. The 160 kD protein band was excised from the SDS-PAGE gel, digested with trypsin and the amino acid sequences of the isolated peptides were analysed.

Primers corresponding to isolated peptides amplified a 900 bp PCR-fragment from bovine cDNA which was cloned, sequenced and used for screening of a human articular chondrocyte  $\lambda$ ZapII cDNA library to obtain the human integrin  $\alpha$ -subunit homologue. Two overlapping clones, hc1 and hc2 were isolated, subcloned and sequenced. These clones contained 2/3 of the nucleotide sequence including the 3' end of the cDNA. A third clone which contained the 5' end of the  $\alpha 10$  cDNA, was obtained using the RACE technique. Sequence analysis of the 160 kD protein sequence showed that it was a member of the integrin  $\alpha$ -subunit family and the protein was named  $\alpha 10$ .

The deduced amino acid sequence of  $\alpha 10$  was found to share the general structure of the integrin  $\alpha$ -subunits described in previously published reports (6-21). The large extracellular N-terminal part of  $\alpha 10$  contains a

seven-fold repeated sequence which was recently predicted to fold into a  $\beta$ -propeller domain (32). The integrin subunit  $\alpha 10$  contains three putative divalent cation-binding sites (DxD/NxD/NxxxD) (53), a single spanning transmembrane domain and a short cytoplasmic domain. In contrast to most  $\alpha$ -integrin subunits the cytoplasmic domain of  $\alpha 10$  does not contain the conserved sequence KxGFF (R/K) R. The predicted amino acid sequence in  $\alpha 10$  is KLGFFAH. Several reports indicate that the integrin cytoplasmic domains are crucial in signal transduction (54) and that membrane-proximal regions of both  $\alpha$ - and  $\beta$ -integrin cytoplasmic domains are involved in modulating conformation and affinity state of integrins (55-57). It is suggested that the GFFKR motif in  $\alpha$ -chains are important for association of integrin subunits and for transport of the integrin to the plasma membrane (58). The KxGFFKR domain has been shown to interact with the intracellular protein calreticulin (59) and interestingly, calreticulin-null embryonic stem cells are deficient in integrin-mediated cell adhesion (60). It is therefore possible that the sequence KLGFFAH in  $\alpha 10$  have a key function in regulating the affinity between  $\alpha 10\beta 1$  and matrix proteins.

Integrin  $\alpha$  subunits are known to share an overall identity of 20-40% (61). Sequence analysis showed that the  $\alpha 10$  subunit is most closely related to the I-domain containing  $\alpha$ -subunits with the highest identity to  $\alpha 1$  (37%) and  $\alpha 2$  (35%). The integrins  $\alpha 1\beta 1$  and  $\alpha 2\beta 1$  are known receptors for both collagens and laminins (24;62;63) and we have also recently demonstrated that  $\alpha 2\beta 1$  interacts with the cartilage matrix protein chondroadherin (42). Since  $\alpha 10\beta 1$  was isolated on a collagen type II-Sepharose, we know that collagen type II is a ligand for  $\alpha 10\beta 1$ . We have also shown by affinity purification experiments that  $\alpha 10\beta 1$  interacts with collagen type I but it remains to be seen whether laminin or chondroadherin are also ligands for this integrin.

The  $\alpha 10$  associated  $\beta$ -chain migrated as the  $\beta 1$  integrin subunit both under reducing and non-reducing conditions. To verify that the  $\alpha 10$  associated  $\beta$ -chain indeed is  $\beta 1$ , chondrocyte lysates were immunoprecipitated with  
5 antibodies against  $\alpha 10$  or  $\beta 1$  followed by Western blot using antibodies against the  $\beta 1$ -subunit. These results clearly demonstrated that  $\alpha 10$  is a member of the  $\beta 1$ -integrin family. However, the possibility that  $\alpha 10$  combine also with other  $\beta$ -chains can not be excluded..

10 A polyclonal peptide antibody raised against the cytoplasmic domain of  $\alpha 10$  precipitated two protein bands with  $M_r$  of approximately 160 kD ( $\alpha 10$ ) and 125 kD ( $\beta 1$ ) under reducing conditions. Immunohistochemistry using the  $\alpha 10$ -antibody showed staining of the chondrocytes in tis-  
15 sue sections of human articular cartilage. The antibody staining was clearly specific since preincubation of the antibody with the  $\alpha 10$ -peptide completely abolished the staining. Immunohistochemical staining of mouse limb sections from embryonic tissue demonstrated that  $\alpha 10$  is  
20 upregulated during condensation of the mesenchyme. This indicate that the integrin subunit  $\alpha 10$  is important during the formation of cartilage. In 3 day old mice  $\alpha 10$  was found to be the dominating collagen binding integrin subunit which point to that  $\alpha 10$  has a key function in  
25 maintaining normal cartilage functions.

Expression studies on the protein and mRNA level show that the distribution of  $\alpha 10$  is rather restrictive. Immunohistochemistry analyses have shown that  $\alpha 10$  integrin subunit is mainly expressed in cartilage but it is  
30 also found in perichondrium, periosteum, ossification groove of Ranvier, in fascia surrounding tendon and skeletal muscle and in the tendon-like structures in the heart valves. This distribution point to that  $\alpha 10$  integrin subunit is present also on fibroblasts and  
35 osteoblasts. PCR amplification of cDNA from different cell types revealed the presence of an alternatively spliced  $\alpha 10$  integrin subunit. This spliced  $\alpha 10$  was domi-

nating in fibroblasts which suggests that  $\alpha 10$  in fibroblasts may have a different function compared to  $\alpha 10$  present on chondrocytes.

Expression of the integrin subunit  $\alpha 10$  was found to decrease when chondrocytes were cultured in monolayer. In contrast, the expression of  $\alpha 10$  was found to increase when the cells were cultured in alginate beads. Since the latter culturing model is known to preserve the phenotype of chondrocytes the results suggest that  $\alpha 10$  can function as marker for a differentiated chondrocyte.

Adhesion between tendon/ligaments and the surrounding tissue is a well-known problem after infection, injury and after surgical intervention. Adhesion between tendon and tendon sheets impairs the gliding function and cause considerable problems especially during healing of tendons in e.g. the hand and fingers leading to functional incapacity. The localisation of the  $\alpha 10$  integrin subunit in the fascia of tendon and skeletal muscle makes  $\alpha 10$  a possible target for drugs and molecules with anti-adhesive properties that could prevent impairment of the function of tendon/ligament. The integrin subunit  $\alpha 10$  can also be a target for drugs or molecules with anti-adhesive properties in other tissues where adhesion is a problem.

25

## EXAMPLES

### Example 1

Affinity purification of the  $\alpha 10$  integrin subunit on collagen type II-Sepharose.

#### Materials and Methods

Bovine chondrocytes, human chondrocytes or human chondrosarcoma cells were isolated as described earlier [Holmvalld et al, Exp Cell Res, 221, 496-503 (1995), Camper et al, JBC, 273, 20383-20389 (1998)]. A Triton X-100 lysate of bovine chondrocytes was applied to a fibronectin-Sepharose precolumn followed by a collagen

type II-Sepharose column and the integrin subunit  $\alpha 10$  was eluted from the collagen type II-column by EDTA (Camper et al, JBC, 273, 20383-20389 (1998). The eluted proteins were precipitated by methanol/chloroform, separated by SDS-PAGE under reducing conditions and stained with Coomassie blue. (Camper et al, JBC, 273, 20383-20389 (1998). Peptides from the  $\alpha 10$  protein band were isolated by in-gel digestion with a trypsin and phase liquid chromatography and sequenced by Edman degradation (Camper et al, JBC, 273, 20383-20389 (1998).

Results

Fig 1 shows EDTA-eluted proteins from the fibronectin-Sepharose (A), flow-through from the collagen type II-Sepharose column (B) and EDTA-eluted proteins from the collagen type II-Sepharose (C). The  $\alpha 10$  integrin subunit (160 kDa) which was specifically eluted from the collagen type II column is indicated with an arrow. Figure 2 shows the amino acid sequences of six peptides that were isolated from the bovine integrin subunit  $\alpha 10$ . Figures 3 a, b, and c show that the  $\alpha 10$  integrin subunit is present on bovine chondrocytes (3a), human chondrocytes (3b) and human chondrosarcoma cells (3c). The affinity for collagen type II, the coprecipitation with  $\beta 1$ -integrin subunit and the molecular weight of 160 kDa under reducing conditions identify the  $\alpha 10$  integrin subunit on the different cells. These results show that  $\alpha 10$  can be isolated from chondrocytes and from chondrosarcoma cells.

## Example 2

Amplification of PCR fragment corresponding to bovine  $\alpha 10$  integrin subunit.

### Materials and methods

The degenerate primers GAY AAY ACI GCI CAR AC (DNTAQT, forward) and TIA TIS WRT GRT GIG GYT (EPHHSI, reverse) were used in PCR (Camper et al, JBC, 273, 20383-20389 (1998) to amplify the nucleotide sequence corresponding to the bovine peptide 1 (Figure 2). A 900 bp

PCR-fragment was then amplified from bovine cDNA using an internal specific primer TCA GCC TAC ATT CAG TAT (SAYIQY, forward) corresponding to the cloned nucleotide sequence of peptide 1 together with the degenerate primer ICK RTC CCA RTG ICC IGG (PGHWDR, reverse) corresponding to the bovine peptide 2 (Figure2). Mixed bases were used in positions that were twofold degenerate and inosines were used in positions that are three- or fourfold degenerate. mRNA isolation and cDNA synthesis was done as earlier described (Camper et al, JBC, 273, 20383-20389 (1998)). The purified fragment was cloned, purified and sequenced as earlier described (Camper et al, JBC, 273, 20383-20389 (1998)).

#### Results

The nucleotide sequence of peptide 1 (Figure 2) was obtained by PCR-amplification, cloning and sequencing of bovine cDNA. From this nucleotide sequence an exact primer was designed and applied in PCR-amplification with degenerate primers corresponding to peptides 2-6 (Figure 2). Primers corresponding to peptides 1 and 2 amplified a 900 bp PCR-fragment from bovine cDNA (Figure 4).

#### Example 3

Cloning and sequence analysis of the human  $\alpha 10$  integrin subunit

##### Material and methods

The cloned 900bp PCR-fragment, corresponding to bovine  $\alpha 10$ -integrin, was digoxigenin-labelled according to the DIG DNA labelling kit (Boehringer Mannheim) and used as a probe for screening of a human articular chondrocyte  $\lambda$ ZapII cDNA library (provided by Michael Bayliss, The Royal Veterinary Basic Sciences, London, UK) (52). Positive clones containing the pBluescript SK+ plasmid with the cDNA insert were rescued from the ZAP vector by *in vivo* excision as described in the ZAP-cDNA<sup>®</sup> synthesis kit (Stratagene). Selected plasmids were purified and

sequenced as described earlier (Camper et al, JBC, 273, 20383-20389 (1998)) using T3, T7 and internal specific primers. To obtain cDNA that encoded the 5' end of  $\alpha 10$  we designed the primer AAC TCG TCT TCC AGT GCC ATT CGT GGG (reverse; residue 1254-1280 in  $\alpha 10$  cDNA) and used it for rapid amplification of the cDNA 5' end (RACE) as described in the Marathon™ cDNA Amplification kit (Clontech INC., Palo Alto, CA).

#### Results

- Two overlapping clones, hc1 and hc2 (Figure 5), were isolated, subcloned and sequenced. These clones contained 2/3 of the nucleotide sequence including the 3' end of the cDNA. A third clone (racel; Figure 5), which contained the 5' end of the  $\alpha 10$  cDNA, was obtained using the RACE technique. From these three overlapping clones of  $\alpha 10$  cDNA, 3884 nucleotides were sequenced. The nucleotide sequence and deduced amino acid sequence is shown in Figure 6. The sequence contains a 3504-nucleotide open reading frame that is predicted to encode a 1167 amino acid mature protein. The signal peptide cleavage site is marked with an arrow, human homologues to bovine peptide sequences are underlined and the I-domain is boxed. Metal ion binding sites are indicated with a broken underline, potential N-glycosylation sites are indicated by an asterisk and the putative transmembrane domain is double underlined. The normally conserved cytoplasmic sequence is indicated by a dot and dashed broken underline.

Sequence analysis demonstrate that  $\alpha 10$  is a member of the integrin  $\alpha$ -subunit family.

#### Example 4

Identification of a clone containing a splice variant of  $\alpha 10$

One clone which was isolated from the human chondrocyte library (see Example 3) contained a sequence that was identical to the sequence of  $\alpha 10$  integrin subunit except that the nucleotides between nt positions

2942 and 3055 were deleted. The splice variant of  $\alpha 10$  was verified in PCR experiment using primers flanking the splice region (see figure 14).

## 5 Example 5

Identification of  $\alpha 10$  integrin subunit by Northern blot

### Material and methods

- Bovine chondrocyte mRNA was purified using a
- 10 QuickPrep<sup>®</sup> Micro mRNA Purification Kit (Pharmacia Biotech, Uppsala, Sweden), separated on a 1% agarose-formaldehyde gel, transferred to nylon membranes and immobilised by UV crosslinking. cDNA-probes were 32P-labelled with Random Primed DNA Labeling Kit (Boehringer Mannheim). Filters
- 15 were prehybridised for 2-4 hours at 42°C in 5x SSE, 5x Denharts solution, 0.1 % SDS, 50 µg/ml salmon sperm DNA and 50% formamide and then hybridised over night at 42 °C with the same solution containing the specific probe (0.5-1 x 10<sup>6</sup> cpm/ml). Specifically bound cDNA-
- 20 probes were analysed using the phosphorimager system (Fuji). Filters were stripped by washing in 0.1% SDS, for 1 hour at 80°C prior to re-probing. The  $\alpha 10$ -integrin cDNA-probe was isolated from the racel-containing plasmid using the restriction enzymes BamHI (GIBCO BRL) and NcoI
- 25 (Boehringer Mannheim). The rat  $\beta 1$ -integrin cDNA probe was a kind gift from Staffan Johansson, Uppsala, Sweden.
- Results

- Northern blot analysis of mRNA from bovine chondrocytes showed that a human  $\alpha 10$  cDNA-probe hybridised with
- 30 a single mRNA of approximately 5.4 kb (Figure 7). As a comparison, a cDNA-probe corresponding to the integrin subunit  $\alpha 1$  was used. This cDNA-probe hybridised a mRNA-band of approximately 3.5 kb on the same filter. These results show that a cDNA-probe against  $\alpha 10$  can be used to
- 35 identify the  $\alpha 10$  integrin subunit on the mRNA level.



## 22

## Example 6

Preparation of antibodies against the integrin subunit  $\alpha 10$

- A peptide corresponding to part of the  $\alpha 10$  cytoplasmic domain, Ckkipееееkreekle (see figure 6) was synthesised and conjugated to keyhole limpet hemocyanin (KLH). Rabbits were immunised with the peptide-KLH conjugate to generate antiserum against the integrin subunit  $\alpha 10$ . Antibodies recognising  $\alpha 10$  were affinity purified on an peptide-coupled column (Innovagen AB).

## Example 7

Immunoprecipitation of the integrin subunit  $\alpha 10$  from chondrocytes

## 15 Material and methods

- Human chondrocytes were  $^{125}\text{I}$ -labelled, lysed with Triton X-100 and immunoprecipitated as earlier described (Holmvalld et al, Exp Cell Res, 221, 496-503 (1995), Camper et al, JBC, 273, 20383-20389 (1998)). Triton X-100 lysates of  $^{125}\text{I}$ -labeled human chondrocytes were immunoprecipitated with polyclonal antibodies against the integrin subunits  $\beta 1$ ,  $\alpha 1$ ,  $\alpha 2$ ,  $\alpha 3$  or  $\alpha 10$ . The immunoprecipitated proteins were separated by SDS-PAGE (4-12%) under non-reducing conditions and visualised using a phosphor-imager. Triton X-100 lysates of human chondrocytes immunoprecipitated with  $\alpha 10$  or  $\beta 1$  were separated by SDS-PAGE (8%) under non-reducing conditions and analysed by Western blot using the polyclonal  $\beta 1$  antibody and chemiluminescent detection as described in Camper et al, JBC, 273, 20383-20389 (1998).

## Results

- The polyclonal peptide antibody, raised against the cytoplasmic domain of  $\alpha 10$ , precipitated two protein bands with Mr of approximately 160 kD ( $\alpha 10$ ) and 125 kD ( $\beta 1$ ) under reducing conditions. The  $\alpha 10$  associated  $\beta$ -chain migrated as the  $\beta 1$  integrin subunit (Figure 8a). To verify that the  $\alpha 10$  associated  $\beta$ -chain in chondrocytes

indeed is  $\beta 1$ , chondrocyte lysates were immunoprecipitated with antibodies against  $\alpha 10$  or  $\beta 1$  followed by Western blot using antibodies against the  $\beta 1$ -subunit (Figure 8b). These results clearly demonstrated that  $\alpha 10$  is a member of the  $\beta 1$ -integrin family. However, the results do not exclude the possibility that  $\alpha 10$  can associate with other  $\beta$ -chains in other situations.

#### Example 8

10 Immunohistochemical staining of the integrin subunit  $\alpha 10$  in human and mouse cartilage

#### Material and methods

Frozen sections of adult cartilage (trochlear groove) obtained during surgery (provided by Anders Lindahl, Salgrenska Hospital, Gothenburg, Sweden and frozen sections from of 3 day old mouse limb were fixed and prepared for immunohistochemistry as earlier described (Camper et al, JBC, 273, 20383-20389 (1998)). Expression of  $\alpha 10$  integrin subunit was analysed using the polyclonal antibody against the cytoplasmic domain as a primary antibody (see Example 6) and a secondary antibody conjugated to peroxidase.

#### Results

25 Figures 9 show immunostaining of human adult articular cartilage.

The  $\alpha 10$ -antibody recognising the cytoplasmic domain of  $\alpha 10$  stained the chondrocytes in tissue sections of human articular cartilage (A). The staining was depleted when the antibody was preincubated with the  $\alpha 10$ -peptide (B). A control antibody recognising the  $\alpha 9$  integrin subunit did not bind to the chondrocyte (C).

Figures 10 shows that the  $\alpha 10$  antibody stain the majority of chondrocytes in the growing bone anlage (a and b). The  $\alpha 10$  antibody also recognised cells in the ossification groove of Ranvier (b), especially the osteoblast in the bone bark which are lining the cartilage in the metaphys are highly positive for  $\alpha 10$ . The

cells in the ossification groove of Ranvier are believed to be important for the growth in diameter of the bone. The integrin subunit  $\alpha 10$  is also highly expressed in perichondrium and periosteum. Cell in these tissues are likely important in the repair of the cartilage tissue. The described localisation of the integrin subunit  $\alpha 10$  suggest that this integrin is important for the function of the cartilage tissue.

#### 10 Example 9

Immunohistochemical staining of the integrin subunit  $\alpha 10$  during mouse development

##### Material and methods

Frozen sections from mouse embryos (13.5 days) were investigated for expression of  $\alpha 10$  by immunohistochemistry as described in Camper et al, JBC, 273, 20383-20389 (1998). Expression of  $\alpha 10$  integrin subunit was analysed using the polyclonal antibody against the cytoplasmic domain as a primary antibody (see Example 6) and a secondary antibody conjugated to peroxidase. The embryo sections were also investigated for expression of integrin subunit  $\alpha 1$  (monoclonal antibody from Pharmingen) and collagen type II (monoclonal antibody, kind gift from Dr John Mo, Lund University, Sweden).

##### 25 Results

Figure 11 show that  $\alpha 10$  integrin subunit is unregulated in the limb when the mesenchymal cells undergo condensation to form cartilage (a). Especially the edge of the newly formed cartilage has high expression of  $\alpha 10$ . The formation of cartilage is verified by the high expression of the cartilage specific collagen type II (b). The control antibody against  $\alpha 1$  integrin subunit showed only weak expression on the cartilage (c). In other experiments expression of  $\alpha 10$  was found in all cartilage containing tissues in the 3 day old mouse including limbs, ribs and vertebrae. The upregulation of  $\alpha 10$  during formation of cartilage suggest that this integrin subunit is

important both in the development of cartilage and bone and in the repair of damaged cartilage tissue.

#### Example 10

- 5 mRNA expression of  $\alpha 10$  in tissues other than articular cartilage

##### Material and methods

- Expression of  $\alpha 10$  integrin subunit was examined on the mRNA level in different human tissues. A Northern dot blot with immobilised mRNA from the listed tissues in Figure 12 was hybridised with an  $\alpha 10$  integrin cDNA probe isolated from the race 1-containing plasmid using the restriction enzymes *Bam*H1 and *Nco*I. The degree of hybridisation was analysed using a phospho imager. The following symbols denote mRNA level in increasing order: -, +, ++, +++, +++++.
- 15

##### Results

- Analysis of the hybridised mRNA showed that  $\alpha 10$  was expressed in aorta, trachea, spinal cord, heart, lung, and kidney (Figure 12). All other tissues appeared negative for  $\alpha 10$  expression. These results point to a restricted distribution of the  $\alpha 10$  integrin subunit.
- 20

#### Example 11

- 25 Immunohistochemical staining of  $\alpha 10$  in fascia around tendon and skeletal muscle and in tendon structures in heart valves.

##### Materials and methods

- Frozen sections of adult cartilage (trochlear groove) obtained during surgery (provided by Anders Lindahl, Salgrenska Hospital, Gothenburg, Sweden and frozen sections from of 3 day old mouse limb were fixed and prepared for immunohistochemistry as earlier described (Camper et al, JBC, 273, 20383-20389 (1998)). Expression of  $\alpha 10$  integrin subunit was analysed using the polyclonal antibody against the cytoplasmic domain as a pri-
- 30
- 35

mary antibody (see Example 6) and a secondary antibody conjugated to peroxidase.

#### Results

As shown in figures 13 expression of  $\alpha 10$  was found in the fascia surrounding tendon (a) and skeletal muscle (b) and in the tendon structures in the heart valves (c). This localisation suggest that  $\alpha 10$  can bind to other matrix molecules in addition to the cartilage specific collagen type II. The localisation of the integrin  $\alpha 10$  on the surface of tendons indicate that  $\alpha 10$  can be involved in unwanted adhesion that often occurs between tendon/ligaments and the surrounding tissue after infection, injury or after surgery.

#### 15 Example 12

mRNA expression of  $\alpha 10$  integrin subunit in chondrocytes, endothelial cells and fibroblasts.

#### Material and methods

Isolation of mRNA, synthesis of cDNA and PCR amplification was done as earlier described (Camper et al, JBC, 273, 20383-20389 (1998)).

#### Results

Figure 14 shows PCR amplification of  $\alpha 10$  cDNA from human articular chondrocytes (lanes A6 and B1), human umbilical vein endothelial cells (lane A2), human fibroblasts (lane A4) and rat tendon (Fig 14b, lane B2). Lanes 1, 3, and 5 in figure 14 A show amplified fragments corresponding to the integrin subunit  $\alpha 2$  in endothelial cells, fibroblasts and chondrocytes, respectively. cDNA-primers corresponding to the  $\alpha 10$  sequence positions nt 2919-2943 (forward) and nt 3554-3578 (reverse) (see Figure 6) were used to amplify  $\alpha 10$  cDNA from the different cells. The figure shows that  $\alpha 10$  was amplified in all three cell types. Two fragments of  $\alpha 10$  was amplified which represent the intact form of  $\alpha 10$  (larger fragment) and a splice variant (smaller fragment). The larger frag-

ment was dominating in chondrocytes while the smaller fragment was more pronounced in tendon (B2).

#### Example 13

##### 5 Construction of $\alpha 10$ mammalian expression vector.

The full length protein coding sequence of  $\alpha 10$  (combined from 3 clones, see figure 6) was inserted into the mammalian expression vector, pcDNA3.1/Zeo (Invitrogen). The vector contains SV40 promoter and Zeosin selection  
10 sequence. The  $\alpha 10$  containing expression vector was transfected into cells that express the  $\beta 1$ -integrin subunit but lack expression of the  $\alpha 10$  subunit. Expression of the  $\alpha 10$  integrin subunit on the cell surface can be analysed by immunoprecipitation and/or flow cytometry using anti-  
15 bodies specific for  $\alpha 10$ . The ligand binding capacity and the function of the inserted  $\alpha 10$  integrin subunit can be demonstrated in cell adhesion experiment and in signalling experiments.

##### 20 Example 14

Construction of mammalian expression vector containing a splice variant of  $\alpha 10$ .

The full length protein coding sequence of the splice variant of  $\alpha 10$  (nt 2942-nt3055 deleted) was  
25 inserted into the mammalian expression vector pcDNA3 (see Example 13). Expression and function of the splice variant can be analysed as described in example 13 and compared with the intact  $\alpha 10$  integrin subunit.

##### 30 Example 15

Partial isolation and characterisation of the  $\alpha 10$  integrin genomic DNA  
Material and methods

Human  $\alpha 10$  cDNA, isolated from the racel-containing  
35 plasmid using the restriction enzymes *Bam*HI (GIBCO BRL) and *Nco*I (Boehringer Mannheim), was  $^{32}$ P-labelled and used as a probe for screening of a mouse 129 cosmid library

(provided by Reinhard Fässler, Lund University). Positive clones were isolated and subcloned. Selected plasmids were purified and sequenced as described earlier (Camper et al, JBC, 273, 20383-20389 (1998)) using T3, T7 and internal specific primers. Primers corresponding to mouse genomic DNA were then constructed and used in PCR to amplify and identify the genomic sequence of  $\alpha 10$  from the cosmid clones.

#### Results

Figure 15 shows 7958 nt of the  $\alpha 10$  gene. This partial genomic DNA sequence of  $\alpha 10$  integrin contains 8 exons, and a Kozak sequence. The mouse genomic  $\alpha 10$  sequence was used to generate a targeting vector for knockout experiments.

#### Example 16

Upregulation of  $\alpha 10$  integrin subunit in chondrocytes cultured in alginate beads

#### Material and methods

Human chondrocytes cultured in monolayer for 2 weeks were detached with trypsin-EDTA and introduced into alginate beads. Chondrocytes cultured in alginate are known to preserve their phenotype while chondrocytes cultured in monolayer are dedifferentiated. After 11 days chondrocytes cultured either in alginate or on monolayer were isolated and surface labelled with  $^{125}\text{I}$ . The  $\alpha 10$  integrin subunit was then immunoprecipitated with polyclonal antibodies recognising the cytoplasmic domain of  $\alpha 10$  (see Example 6 and Camper et al, JBC, 273, 20383-20389 (1998)).

#### Results

As shown in figure 16 chondrocytes cultured in alginate beads (lanes 3 and 4) upregulated their protein expression of  $\alpha 10\beta 1$ . This was in contrast to chondrocytes cultured in monolayer (lanes 1 and 2) which had a very low expression of  $\alpha 10\beta 1$ . Immunoprecipitation with ab control antibody is shown in lanes 1 and 3. It is known that

- chondrocytes preserve their cartilage specific matrixpro-  
duction in alginate cultures but not in monolayer culture  
which point to that alginate preserve the phenotype of  
chondrocytes. These results support that  $\alpha 10$  integrin  
5 subunit can be used as a marker for differentiated chon-  
drocytes.

#### Example 17

- Immunoprecipitation of the  $\alpha 10$  integrin subunit from  
10 human smooth muscle cells.  
Material and methods

- Human smooth muscle cells were isolated from human  
aorta. After one week in culture the cells were  $^{125}\text{I}$ -  
labelled, lysed and immunoprecipitated with antibodies  
15 against the integrin subunit  $\beta 1$  (lane 1),  $\alpha 1$  (lane 2),  $\alpha 2$   
(lane 3),  $\alpha 10$  (lane 4),  $\alpha 3$  (lane 5), control (lane 6)  
(Figure 17). The experiment was done as described in  
Example 7.

#### Results

- 20 The  $\alpha 10$  antibody precipitated two bands from the  
smooth muscle cells corresponding to the  $\alpha 10$  and the  $\beta 1$   
integrin subunit (Fig. 17).

#### Example 18

- 25 Construction of bacterial expression vector contain-  
ing sequence for  $\alpha 10$  splice region.

- A plasmid for intracellular expression in E. coli  
of the alternatively spliced region (amino acid pos.  
952-986, SEQ. ID 1) was constructed as described. The  
30 alternatively spliced region were back-translated using  
the E. coli high frequency codon table, creating a cDNA  
sequence of 96% identity with the original sequence (SEQ.  
ID 1 nucleotide pos 2940-3044). Using sequence overlap  
extension (Horton et al., Biotechniques 8:528, 1990)  
35 primer  $\alpha 10\text{pfor}$  (tab. I) and  $\alpha 10\text{prev}$  (tab. I) was used  
to generate a double stranded fragment encoding the  $\alpha 10$   
amino acid sequence. This fragment was used as a PCR



template with primers  $\alpha 10$ pfor2 (tab. I) and  $\alpha 10$ prev2 (tab. I) in order to generate restriction enzyme site for sub-cloning in a pET vector containing the Z-domain of staphylococcal protein A, creating a fusion of the  $\alpha 10$  spliced region with the amino terminal of the Z-domain with trombin cleavage site residing in-between. The fragment generated in the second PCR reaction is shown (SEQ ID No. 3) also indicating the unique restriction enzymes used for sub-cloning in the expression vector.

Table I

$\alpha 10$ pfor	5'- GTT CAG AACCTGGGTTGCTACGTTGTTCCGGTCTGATCATCTCCGC TCTGCTGCCGGCTGT-3'
$\alpha 10$ pfor2	5'-GGGGCATATGGTTCAGAACCTGGGTTGCTACGTTG-3'
$\alpha 10$ prev	5'- GATAACCTGGGACAAGCTTAGGAAGTAGTTACCACCGTGAGCAACAG CCGGCAGCAGAGCGGA-3'
$\alpha 10$ prev2	5'- GGGGGGATCCGCGCGGCACCAGGCCGCTGATAACCTGGGACAAGCTT AGGAAGT-3'

## REFERENCES

1. Springer, T.A. (1990) *Nature* **346**, 425-434
2. Ruoslahti, E. (1991) *J.Clin.Invest.* **87**, 1-5
3. Hynes, R.O. (1992) *Cell* **69**, 11-25
- 5 4. Hemler, M.E. (1988) *Immunol.Today* **9**, 109-113
5. Yamada, K.M. (1991) *J.Biol.Chem.* **266**, 12809-12812
6. Palmer, E.L., Ruegg, C., Ferrando, R., Pytela, R.,  
and Sheppard, D. (1993) *J.Cell Biol.* **123**, 1289-1297
7. Takada, Y., Elices, M.J., Crouse, C., and Hemler,  
10 M.E. (1989) *EMBO J.* **8**, 1361-1368
8. Poncz, M., Eisman, R., Heidenreich, R., Silver, S.M.,  
Vilaire, G., Surrey, S., Schwartz, E., and Bennett,  
J.S. (1987) *J.Biol.Chem.* **262**, 8476-8482
9. Larson, R.S., Corbi, A.L., Berman, L., and Springer,  
15 T. (1989) *J.Cell Biol.* **108**, 703-712
10. Corbi, A.L., Kishimoto, T.K., Miller, L.J., and  
Springer, T.A. (1988) *J.Biol.Chem.* **263**, 12403-12411
11. Argraves, W.S., Suzuki, S., Arai, H., Thompson, K.,  
Pierschbacher, M.D., and Ruoslahti, E. (1987) *J.Cell*  
20 *Biol.* **105**, 1183-1190
12. Corbi, A.L., Miller, L.J., O'Connor, K., Larson,  
R.S., and Springer, T.A. (1987) *EMBO J.* **6**, 4023-4028
13. Briesewitz, R., Epstein, M.R., and Marcantonio, E.E.  
(1993) *J.Biol.Chem.* **268**, 2989-2996
- 25 14. Ziober, B.L., Vu, M.P., Waleh, N., Crawford, J., Lin,  
C.S., and Kramer, R.H. (1993) *J.Biol.Chem.* **268**,  
26773-26783
15. Hogervorst, F., Kuikman, I., van Kessel, A.G., and  
Sonnenberg, A. (1991) *Eur.J.Biochem.* **199**, 425-433
- 30 16. Takada, Y. and Hemler, M.E. (1989) *J.Cell Biol.* **109**,  
397-407
17. Takada, Y., Murphy, E., Pil, P., Chen, C., Ginsberg,  
M.H., and Hemler, M.E. (1991) *J.Cell Biol.* **115**,  
257-266
- 35 18. Van der Vieren, M., Le Trong, H., Wood, C.L., Moore,  
P.F., St.John, T., Staunton, D.E., and Gallatin, W.M.  
(1995) *Immunity*. **3**, 683-690

19. Schnapp, L.M., Breuss, J.M., Ramos, D.M., Sheppard, D., and Pytela, R. (1995) *J.Cell Sci.* 108, 537-544
20. Shaw, S.K., Cepek, K.L., Murphy, E.A., Russell, G.J., Brenner, M.B., and Parker, C.M. (1994) *J.Biol.Chem.* 269, 6016-6025
21. Suzuki, S., Argraves, W.S., Arai, H., Languino, L.R., Pierschbacher, M.D., and Ruoslahti, E. (1987) *J.Biol.Chem.* 262, 14080-14085
22. Ignatius, M.J., Large, T.H., Houde, M., Tawil, J.W., Barton, A., Esch, F., Carbonetto, S., and Reichardt, L.F. (1990) *J.Cell Biol.* 111, 709-720
23. Gullberg, D., Gehlsen, K.R., Turner, D.C., Åhlén, K., Zijenah, L.S., Barnes, M.J., and Rubin, K. (1992) *EMBO J.* 11, 3865-3873
24. Staaz, W.D., Rajpara, S.M., Wayner, E.A., Carter, W.G., and Santoro, S.A. (1989) *J.Cell Biol.* 108, 1917-1924
25. Holmval, K., Camper, L., Johansson, S., Rubin, K., Kimura, J.H., and Lundgren-Åkerlund, E. (1995) *Exp.Cell Res.* 221, 496-503
26. Forsberg, E., Ek, B., Engström, Å., and Johansson, S. (1994) *Exp.Cell Res.* 213, 183-190
27. Wayner, E.A. and Carter, W.G. (1987) *J.Cell Biol.* 105, 1873-1884
28. Weitzman, J.B., Pasqualini, R., Takada, Y., and Hemler, M.E. (1993) *J.Biol.Chem.* 268, 8651-8657
29. Ellices, M.J. and Hemler, M.E. (1989) *Proc.Natl.Acad.Sci.U.S.A.* 86, 9906-9910
30. Languino, L.R., Colella, S., Zanetti, A., Andrieux, A., Ryckewaert, J.J., Charon, M.H., Marchisio, P.C., Plow, E.F., Ginsberg, M.H., Marguerie, G., and et al (1989) *Blood* 73, 734-742
31. Tuckwell, D.S., Humphries, M.J., and Brass, A. (1994) *Cell Adhes.Comm.* 2, 385-402
32. Springer, T.A. (1997) *Proc.Natl.Acad.Sci.U.S.A.* 94, 65-72

33. Colombatti, A., Bonaldo, P., and Doliana, R. (1993) Matrix 13, 297-306
34. Lee, C.H., Bradley, G., and Ling, V. (1995) Cell Growth Differ. 6, 347-354
- 5 35. Calderwood, D.A., Tuckwell, D.S., and Humphries, M.J. (1995) Biochem.Soc.Trans. 23, 504S
36. Kern, A., Eble, J., Golbik, R., and Kuhn, K. (1993) Eur.J.Biochem. 215, 151-159
37. Tuckwell, D.S., Reid, K.B., Barnes, M.J., and  
10 Humphries, M.J. (1996) Eur.J.Biochem. 241, 732-739
38. Kamata, T. and Takada, Y. (1994) J.Biol.Chem. 269, 26006-26010
39. Dürr, J., Goodman, S., Potocnik, A., von der Mark, H., and von der Mark, K. (1993) Exp.Cell Res. 207,  
15 235-244
40. Salter, D.M., Hughes, D.E., Simpson, R., and Gardner, D.L. (1992) Br.J.Rheumatol. 31, 231-234
41. Woods, V.L.J., Schreck, P.J., Gesink, D.S., Pacheco, H.O., Amiel, D., Akeson, W.H., and Lotz, M. (1994) Arthritis Rheum. 37, 537-544  
20
42. Camper, L., Heinegård, D., and Lundgren-Åkerlund, E. (1997) J.Cell Biol 138, 1159-1167
43. Hemler, M.E., Sanchez Madrid, F., Flotte, T.J., Krensky, A.M., Burakoff, S.J., Bhan, A.K., Springer, T.A., and Strominger, J.L. (1984) J.Immunol. 132,  
25 3011-3018
44. Bottger, B.A., Hedin, U., Johansson, S., and Thyberg, J. (1989) Differentiation. 41, 158-167
45. Sommarin, Y. and Heinegård, D. (1983) Biochem.J. 214, 777-784  
30
46. Häuselmann, H.J., Aydelotte, M.B., Schumacher, B.L., Kuettner, K.E., Gitelis, S.H., and Thonar, E.J.M.A. (1992) Matrix 12, 116-129
47. Miller, E.J. (1972) Biochemistry 11, 4903-4909
- 35 48. Wessel, D. and Flugge, U.I. (1984) Anal.Biochem. 138, 141-143

49. Blobel, G. and Dobberstein, B. (1975) *J.Cell Biol.* 67, 835-851
50. Hellman, U. (1997) in *Protein structure analysis. Preparation, characterization, and microsequencing* (Kamp, R.M., Choli-Papadopolou, T., and Wittmann-Liebold, B., eds) pp. 97-104, Springer-Verlag, Heidelberg
51. Charles, I.G., Palmer, R.M., Hickery, M.S., Bayliss, M.T., Chubb, A.P., Hall, V.S., Moss, D.W., and Moncada, S. (1993) *Proc.Natl.Acad.Sci.U.S.A.* 90, 11419-11423
52. Tuckwell, D.S., Brass, A., and Humphries, M.J. (1992) *Biochem.J.* 285, 325-331
53. Dedhar, S. and Hannigan, G.E. (1996) *Curr.Opin.Cell Biol.* 8, 657-669
54. Hughes, P.E., O'Toole, T.E., Ylanne, J., Shattil, S.J., and Ginsberg, M.H. (1995) *J.Biol.Chem.* 270, 12411-12417
55. Puzon McLaughlin, W., Yednock, T.A., and Takada, Y. (1996) *J.Biol.Chem.* 271, 16580-16585
56. O'Toole, T.E., Katagiri, Y., Faull, R.J., Peter, K., Tamura, R., Quaranta, V., Loftus, J.C., Shattil, S.J., and Ginsberg, M.H. (1994) *J.Cell Biol.* 124, 1047-1059
57. De Melker, A.A., Kramer, D., Kuikman, I., and Sonnenberg, A. (1997) *Biochem J* 529-537
58. Rojiani, M.V., Finlay, B.B., Gray, V., and Dedhar, S. (1991) *Biochemistry* 30, 9859-9866
59. Coppolino, M.G., Woodside, M.J., Demarex, N., Grinstein, S., St Arnaud, R., and Dedhar, S. (1997) *Nature* 386, 843-847
60. Hynes, R.O. (1992) *Curr.Opin.Genet.Dev.* 2, 621-624
61. Santoro, S.A. (1986) *Cell* 46, 913-920
62. Languino, L.R., Gehlsen, K.R., Wayner, E., Carter, W.G., Engvall, E., and Ruoslahti, E. (1989) *J.Cell Biol.* 109, 2455-2462

63. Yokosaki, Y., Monis, H., Chen, J., and Sheppard, D.  
(1996) J.Biol.Chem. 271, 24144-24150

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197  
2198  
2199  
2200  
2201  
2202  
2203  
2204  
2205  
2206  
2207  
2208  
2209  
2210  
221



AGCTCTGCTTCAGTTCTGGGATATGTGCCCGTGTGGATGCTTCATTCACGCCTCAGGGA  
 421 -----+-----+ 480  
 TCGAGACAGAAGTCAAGACCCCTATACACGGGCACACCTACGAAGTAAGTCCGAGTCCCT  
 a S S V F S S G I C A R V D A S F Q P Q G -  
 AGCCTGGCACCCACTGCCAACGCTGCCAACATACATGGATGTTGTCATTGTCTTGGAT  
 481 -----+-----+ 540  
 TCGGACCGTGGGTGACGGGTTGCGACGGGTGTATGTACCTACAACAGTAACGAGAACCTA  
 a S L A P T A Q R C P T Y M D V V I V L D -  
 GGCCTCCAACAGCATCTACCCCTGGTCTGAAGTTCAGACCTTCCTACGAAGACTGGTAGGG  
 541 -----+-----+ 600  
 CCGAGGTTGTCGTAGATGGGGACAGACTTCAAGTCTGGAAGGATGCTTCTGACCATCCC  
 a G S N S I Y P W S E V Q T F L R R L V G -  
 AAATGTTTATGTACCCAGAACAGATACAGGTGGGACTGGTACAGTATGGGGGAGAGCCCT  
 601 -----+-----+ 660  
 TTGACAAATAACTGGGTCTTGCTATGTATCCACCTGACCATGTATACCCCTCTCGGGA  
 a K L F I D P E Q I Q V G L V Q Y G E S P -  
 GTACATGAGTGGTCCCTGGGAGATTTCCGAACGAAGGAAGAGTGGTGAGAGCAGCAAG  
 661 -----+-----+ 720  
 CATGTACTCACCAGGACCCCTCTAAAGGCTTGCTTCTCTTCCACTCTCGTCTGTTTC  
 a V H E W S L G D F R T K E E V V R A A K -  
 AACCTCAGTCGCGGGGAGGGACGAGAACAAGAGCTGCCCAAGCAATAATGGTGGCCTGC  
 721 -----+-----+ 780  
 TTGGAGTCAGCCGCCCTCCTGCTCTTTGTTCTGACGGGTTGTTATTACCACGGGAGC  
 a N L S R R E G R E T K T A Q A I M V A C -  
 ACAGAAGGTTTCAGTCAGTCCCATGGGGCCGACCGAGGCTGCCAGGCTACTGGTGGTT  
 781 -----+-----+ 840  
 TGTCTTCCCAAGTCAGTCAGGATACCCCGGCTGGGCTCCGACGGTCCGATGACCACTAA  
 a T E G F S Q S H G G R P E A A R L L V V -  
 GTCACTGATGGAGAGTCCCATGATGGAGAGGAGCTTCTTCGACACTAAAGGCCTGTGAG  
 841 -----+-----+ 900  
 CAGTGACTACCTCTCAGGCTACTACCTCTCTCGAAGGACGTCTGATTTCCGACACTC  
 a V T D G E S H D G E E L P A A L K A C E -  
 GCTGGAAGAGTGACACGCTATGGGATTGCAGTCTTGGTCACTACCTCCGGCGGCAGCGA  
 901 -----+-----+ 960  
 CGACCTTCTCACTGTGCGATACCTTAACGTGAGGAACAGTGATGGAGGCCCGCTCGCT  
 a A G R V T R Y G I A V L G H Y L R R Q R -  
 GATCCCAGCTCTTTCTGAGAGAAATTAGAACTATTGCCAGTGATCCAGATGAGCGATT  
 961 -----+-----+ 1020  
 CTAGGGTCGAGAAAGGACTCTCTTTAATCTTGATAACGGTCACTAGGTCTACTCGCTAAG  
 a D P S S F L R E I R T I A S D P D E R F -  
 TTCTTCATGTACAGATGAGGCTGCTCTGACTGACATTGTGGATGCACTAGGAGATCGG  
 1021 -----+-----+ 1080  
 AAGAAGTTACAGTGTCTACTCCGACGAGACTGACTGTAAACCTACGTGATCCTCTAGCC  
 a F F N V T D E A A L T D I V D A L G D R -



1081 ATTTTGGCCTTGAAGGGTCCCATGCAGAAAACGAAAGCTCCTTTGGGCTGGAATGTCT 1140  
 TAAAAACCGAACTTCCCAGGGTACGTCTTTTGGCTTCGAGGAAACCCGACTTTACAGA  
 a I F G L E G S H A E N E S S F G L E M S -  
 1141 CAGATTGGTTTCTCCACTCATCGGCTAAGGATGGGATTCTTTTGGGATGGTGGGGGCC 1200  
 GTCTAACCAAAGAGGTGAGTAGCCGATTTCCTACCTTAAGAAAACCTACCACCCCGG  
 a Q I G F S T H R L K D G I L F G M V G A -  
 1201 TATGACTGGGAGGCTCTGTGCTATGGCTTGAAGGAGGCCACCGCTTTTCCCCACGA 1260  
 ATACTGACCCCTCCGAGACAGATACCGAACTTCCTCCGTGGCGGAAAAGGGGGTGCT  
 a Y D W G G S V L W L E G G H R L F P P R -  
 1261 ATGGCACTGGAAGACGAGTTCCTCCCTGCACTGCAGAACCATGCAGCTACCTGGGTAC 1320  
 TACCGTGACCTTCTGCTCAAGGGGGAGCTGACGTCTGGTACGTGGGATGACCCCAATG  
 a M A L E D E F P P A L Q N H A A Y L G Y -  
 1321 TCTGTTTCTTCCATGCTTTTGGGGGTGGAGCGCGCTGTTTCTCTGGGGCTCCTCGA 1380  
 AGACAAGAGGTACGAAAACGCCCCACCTGCGGCGGACAAAGAGAGACCCGAGGAGCT  
 a S V S S M L L R G G R R L F L S G A P R -  
 1381 TTTAGACATCGAGAAAAGTCATCGCCTTCCAGCTTAAGAAAGATGGGGCTGTGAGSGTT 1440  
 AAATCTAGTCTCCTTTTCACTAGCGGAAGGTGGAATTCTTTTACCCCGAGACTCCCAA  
 a F R H R G K V I A F Q L K K D G A V R V -  
 1441 GCCCAGAGCCTCCAGGGGAGCAGATTGGTTCATACTTTGGCAGTGAGCTCTGCCCATG 1500  
 CGGGTCTCGGAGGTCCCCCTCGTCTAACCAAGTATGAAACCGTCACTCGAGACGGGTAA  
 a A Q S L Q G E Q I G S Y F G S E L C P L -  
 1501 GATACAGATAGGGATGGAACAACCTGATGCTTACTTGTGGCTGCCCCATGTTCTCTGGGA 1560  
 CTATGCTATCCCTACCTTGTGACTACAGAATGAACCCGACGGGGGTACAAGGACCT  
 a D T D R D G T T D V L L V A A P M F L G -  
 1561 CCCCAAGCAAGGAAACAGGAAGTGTATGTATCTGGTAGGCCAGCAGCTCTTGCTG 1620  
 GGGGCTCTTGTCTTGTCTCTGCAAAATACATAGACCATCGGCTCGTACGGAACGAC  
 a P Q N K E T G R V Y V Y L V G Q Q S L L -  
 1621 ACCCTCAAGGAACACTTCAGCCAGAACCCCCCAGGATGCTCGGTTTGGCTTTGCCATG 1680  
 TGGGAGGTTCCTTGTGAAGTCGCTCTTGGGGGGGTCTCTACGAGCCAACCGAAACGGTAC  
 a T L Q G T L Q P E P P Q D A R F G F A M -  
 1681 GGAGCTCTTCTGATCTGAACCAAGATGGTTTGTGATGTGGCTGTGGGGGGCGCTCTG 1740  
 CCTCGAGAAGGACTAGACTTGGTCTACCAAAACGACTACACGACACCCCCCGGAGAC  
 a G A L P D L N Q D G F A D V A V G A P L -

1741 GAAGATGGGCACCGAGGACTGTACCTGTACCATGGAAACCAGAGTGGAGTCAGGCCC 1800  
 CTTCTACCCGGTCCCTCGTGACATGGACATGGTACCTGGGTCTCACTCAGTCCGGG  
 a E D G H Q G A L Y L Y H G T Q S G V R P -  
 1801 CATCCTGCCACAGGATTGCTGCTGCCTCCATGCCACATGCCCTCAGCTACTTTGGCCGA 1860  
 GTAGGACGGGTCTCCTAACGACGACGAGGTACGGGTGTACGGGAGTCGATGAACCGGCT  
 a H P A Q R I A A A S M P H A L S Y F G R -  
 1861 AGTGTGGATGGTCGGCTAGATCTGGATGGAGATGATCTGGTCGATGTGGCTGTGGGTGCC 1920  
 TCACACCTACCAGCGATCTAGACCTACCTCTACTAGACCAGTACACCGACACCCACGG  
 a S V D G R L D L D G D D L V D V A V G A -  
 1921 CAGGGGCGAGCCATCCTGCTCAGCTCCCGGCCATTGTCCATCTGACCCCATCATGGAG 1980  
 GTCCCCGTCGGTAGGACGAGTCGAGGGCCGGGTAAACAGGTAGACTGGGTATGTGACCTC  
 a Q G A A I L L S S R P I V H L T P S L E -  
 1981 GTGACCCACAGGCCATCAGTGTGGTTCAGAGGACTGTAGGCGGCGAGGCCAAGAAGCA 2040  
 CACTGGGGTGTCCGGTAGTCACACCAAGTCTCCTGACATCGCCGCTCCGGTCTCTCGT  
 a V T P Q A I S V V Q R D C R R R G Q E A -  
 2041 GTCTGTCTGACTGCAGCCCTTTGCTTCCAAGTGACCTCCCGTACTCTGGTCTGGGAT 2100  
 CAGACAGACTGACGTCGGGAAACGAAGGTTCACTGAGGGCATGAGGACCAGCGACCCCTA  
 a V C L T A A L C F Q V T S R T P G R W D -  
 2101 CACCAATTCTACATGAGGTTTACCGCATCACTGGATGAATGGACTGCTGGGGCACGTGCA 2160  
 GTGGTTAAGATGTACTCCAAGTGGCGTAGTGACCTACTTACCTGACGACCCCGTGACGT  
 a H Q F Y M R F T A S L D E W T A G A R A -  
 2161 GCATTTGATGGCTCTGGCCAGAGGTTGTCCCTCCGAGGCTCCGGCTCAGTGTGGGGAAT 2220  
 CGTAAACTACCGAGACCGGTCTCCAACAGGGGAGCCTCCGAGGCCAGTCAACACCCCTTA  
 a A F D G S G Q R L S P R R L R L S V G N -  
 2221 GTCACTTGTGAGCAGCTACACTTCCATGTGCTGGATACATCAGATTACCTCCGGCCAGTG 2280  
 CAGTGAACACTCGTCGATGTGAAGGTACACGACCTATGTAGTCTAATGGAGGCCGTGAC  
 a V T C E Q L H F H V L D T S D Y L R P V -  
 2281 GCCTTGACTGTGACCTTTGCTTGGACAATACTACAAAGCCAGGGCTGTGCTGAATGAG 2340  
 CGGAACAGACCTGGAAACGGAACCTGTTATGATGTTTCGGTCCCGACACGACTTACTC  
 a A L T V T F A L D N T T K P G P V L N E -  
 2341 GGCTCACCACCTCTATACAAAAGCTGGTCCCTTCTCAAAGGATTGTGGCCCTGACAA 2400  
 CCGAGTGGGTGGAGATATGTTTTCGACCAGGGGAAGAGTTTCTTAACACCGGACCTGTTA  
 a G S P T S I Q K L V P F S K D C G P D N -

2401 GAATGTGTCACAGACCTGGTGCTTCAAGTGAATATGGACATCAGAGGCTCCAGGAAGGCC  
 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+  
 CTTACACAGTGTCTGGACCAAGATTCACCTTATACCTGTAGTCTCCGAGGTCTTCCGG  
  
 a E C V T D L V L Q V N M D I R G S R K A -  
 CCATTTGTGGTTCGAGGTGGCCGGCGGAAGTGTGGTATCTACAACCTCGGAGAAGAGA  
 2461 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2520  
 GGTAAACACCAAGCTCCACCGCGCGCTTTACGACCATAGATGTTGAGACCTCTTGTCT  
  
 a P F V V R G G R R K V L V S T T L E N R -  
 AAGGAAAATGCTTACAATACGAGCCTGAGTATCATCTTCTCTAGAAAACCTCCACCTGGCC  
 2521 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2580  
 TTCTTTTACGAATGTTATGCTCGGACTCATAGTAGAAGAGATCTTTGGAGGTGGACCGG  
  
 a K E N A Y N T S L S I I F S R N L H L A -  
 AGTCTCACTCCTCAGAGAGAGGCCAATAAGGTGGAATGTGCCGCCCTTCTGTCTCAT  
 2581 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2640  
 TCAGAGTGAGGAGTCTCTCTCGGGTATTTCACCTTACACGGCGGGGAGAGCGAGTA  
  
 a S L T P Q R E S P I K V E C A A P S A H -  
 GCCCGGCTCTGCAGTGTGGGCGATCTGTCTTCCAGACTGGAGCCAAGGTGACCTTTCTG  
 2641 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2700  
 CGGCGCGAGACGTACACCCGTAGGACAGAAGTCTGACCTCGGTCCACTGGAAAGAC  
  
 a A R L C S V G H P V F Q T G A K V T F L -  
 CTAGAGTTTGAGTTTAGCTGCTCCTCTCTCCTGAGCCAGGTCTTTGGGAAGCTGACTGCC  
 2701 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2760  
 GATCTCAAACTCAAATCGACGAGGAGAGGAGTCTGGTCCAGAAACCTTCGACTGACGG  
  
 a L E F E F S C S S L L S Q V F G K L T A -  
 AGCAGTGACAGCCTGGAGAGAAATGGCACCCCTTCAAGAAAACACAGCCCGAGCCCTCAGCC  
 2761 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2820  
 TCGTCACTGTCGACCTCTCTTTACCGTGGGAAGTCTTTTGTGTCGGGTCTGGAGTCGG  
  
 a S S D S L E R N G T L Q E N T A Q T S A -  
 TACATCCAATATGAGCCCCACCTCCTGTCTCTAGTGAGTCTACCTGACCCCGTATGAG  
 2821 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2880  
 ATGTAGGTTATACTCGGGGTGGAGGACAAGAGATCACTCAGATGGGACGTGGCGATACTC  
  
 a Y I Q Y E P H L L F S S E S T L H R Y E -  
 GTTCACCCATATGGGACCCCTCCAGTGGGTCTGGCCAGAAATCAAACCACTCTCAGG  
 2881 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 2940  
 CAAGTGGGTATACCTGGGAGGGTCACCCAGGACCGGGTCTTAAGTTTGGTGAGAGTCC  
  
 a V H P Y G T L P V G P G P E F K T T L R -  
 GTTCAGAACCTAGGCTGTATGTGGTCACTGGCCTCATCATCTCAGCCCTCTCTCCAGCT  
 2941 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 3000  
 CAAGTCTTGGATCGACGATACACCACTCACCGGATAGTAGAGTCGGGAGGAAGGTCTGA  
  
 a V Q N L G C Y V V S G L I I S A L L P A -  
 GTGGCCCATGGGGCAATTACTTCCTATCACTGTCTCAAGTCATCACTAACAATGCAAGC  
 3001 -----+-----+-----+-----+-----+-----+-----+-----+-----+-----+ 3060  
 CACCGGGTACCCCGTTAATGAAGGATAGTGACAGAGTTCAGTAGTGATTGTTACGTTCTG  
  
 a V A H G G N Y F L S L S Q V I T N N A S -

TGCATAGTGCAGAACCTGACTGAACCCAGGCCACCTGTGCATCCAGAGGAGCTTCAA  
 3061 -----+-----+-----+-----+-----+ 3120  
 ACGTATCAGCTCTTGGACTGACTTGGGGTCCGGTGGACAGTAGTCTCCTCGAAGTT  
 a C I V Q N L T E P P G P P V H P E E L Q -  
 CACACAAACAGACTGAATGGGAGCAATACTCAGTGTCAAGTGGTGGAGTCCACCTTTGGG  
 3121 -----+-----+-----+-----+-----+ 3180  
 GTGTGTTGTCTGACTTACCTCGTTATGAGTCACAGTCCACCTCCACGGTGGAAACCC  
 a H T N R L N G S N T Q C Q V V R C H L G -  
 CAGCTGGCAAAGGGGACTGAGGTCTCTGTTGGACTATTGAGGCTGGTTCACATGAATTT  
 3181 -----+-----+-----+-----+-----+ 3240  
 GTCGACCGTTTCCCTGACTCCAGAGACAACCTGATAACTCCGACCAAGTGTACTTAA  
 a Q L A K G T E V S V G L L R L V H N E F -  
 TTCCGAAGAGCCAAAGTTCAAGTCCCTGACGGTGGTCAGCACCTTTGAGCTGGGAACCGAA  
 3241 -----+-----+-----+-----+-----+ 3300  
 AAGGCTTCTCGGTTCAGTTTCAGGGACTGCCACAGTCTGTGGAACTCGACCTTTGCGTT  
 a F R R A K F K S L T V V S T F E L G T E -  
 GAGGCGAGTGTCTCTACAGCTGACTGAAGCCTCCCGTTGGAGTGAGAGCCTCTTTGGAGGTG  
 3301 -----+-----+-----+-----+-----+ 3360  
 CTCCTCTCACAGGATGTCTGACTGACTTCGGAGGGCAACCTCACTCTCGAGAGACCTCCAC  
 a E G S V L Q L T E A S R W S E S L L E V -  
 GTTCAGACCCGGCCTATCCTCATCTCCCTGTGGATCCTCATAGGCGAGTGTCTGGGAGGG  
 3361 -----+-----+-----+-----+-----+ 3420  
 CAAGTCTGGGCCGGATAGGAGTAGAGGGACACCTAGGAGTATCCGTACAGGACCCCTCCC  
 a V Q T R P I L I S L W I L I G S V L G G -  
 TTGCTCCTGCTTGTCTCTCTTGTCTTCTGCTGTGGAAGCTTGGCTCTTTGCCATAAG  
 3421 -----+-----+-----+-----+-----+ 3480  
 AACGAGGACGAACGAGAGGAACAGAAGACGGACACCTTCGAACGAAGAAACGGGTATTC  
 a L L L L A L L V F C L W K L G F F A H K -  
 AAAATCCCTGAGGAAGAAAAAGAGAAGAGAAGTTGGAGCAATGATGTAGAATAAGGGT  
 3481 -----+-----+-----+-----+-----+ 3540  
 TTTTAGGGACTCTCTCTTTTCTCTCTCTCAACCTCGTTACTTACATCTTATCCCA  
 a K I P E E E K R E E K L E Q  
 CTAGAAAGTCTCCCTGGCAGCTTTCTTCAAGAGACTTGCATAAAAGCAGAGGTTTGGGG  
 3541 -----+-----+-----+-----+-----+ 3600  
 GATCTTTCAGGAGGGACCGTCCGAAAGAAGTTCTCTGAACGTATTTCTGCTCTCCAAACCCC  
 GCTCAGATGGGACAAGAAGCCGCTCTGAGACTATCTCCCCAGACCAGCAGCCTGACTTGA  
 3601 -----+-----+-----+-----+-----+ 3660  
 CGAGTCTACCTGTTCTTCGGCGGAGACCTGATAGAGGGGTCTGGTCTCGGACTGAAC  
 CTTTGTAGTCTTAGGGATGCTGCTGGCTAGAGATGAGGCTTTACCTCAGACAAGAGAGC  
 3661 -----+-----+-----+-----+-----+ 3720  
 GAAACTCAGGATCCCTACGACGACCGATCTCTACTCCGAAATGGAGTCTGTTCTCTCG

[illegible]

43

(2) INFORMATION FOR SEQ ID NO. 2:

- ```
(i) SEQUENCE CHARACTERISTICS:
  (A) LENGTH: 3779 base pairs
  (B) TYPE: nucleic acid and amino acid
  (C) STRANDEDNESS: double
  (D) TOPOLOGY: linear
  (E)
(i) MOLECULAR TYPE: cDNA
(vi) ORIGINAL SOURCE:
  (A) ORGANISM: human
  (B) CELLTYPE: chondrocyte
```

(xi) SEQUENCE DESCRIPTION: SEQ ID NO. 2:

1 CAGGTCAAGAACCGATCAGGATGTGAACCTCCCTTGGTCACTCACCTGTCTCTGCCCTCG 60  
GTCCAGTCTTTGGCTAGTCCGTACCTTTCAGGGGGAACAGTGAAGTGGACAAGAACGGGGAC  
M E L P F V T H L F L P L -  
61 GTGTCTCTGACAGSTCTCTGCTCCCCCTTTAACTGGATGAACATCACCCACGCCCTATTTC 120  
CACAAAGGACTGTCCAGAGACGAGGGGGAAATTTGCACTACTTGTAGTGGGTGCGGATAAG  
V F L T G L C S P F N L D E H H P R L F -  
121 CCAGGGCCACAGAAGCTGAATTTGGATACAGTGTCTTACAACATGTTGGGGGTGGACAG 180  
GGTCCCGGTGGTCTTCGACTTAAACCTATGTACAGAAATGTTGTACAACCCCCACCTGTTC  
P G P P E A E F G Y S V L Q H V G G G Q -  
181 CGATGGATGCTGGTGGCGCCCCCTGGGATGGGGCTTCAGGCGACCGAGAGGGGGAGCGTT 240  
GCTACTACGACCAACCCGCGGGGACCTACCCGAAGTCCGCTGGCCTCCCCCTGCACAA  
R N W M L V G A P W D G F S G D R R G G D V -  
241 TATCGCTGCCCTGTAGGGGGGGCCCAATGCCCATGTGCGCAAGGGCCACTTAGGTGAC 300  
ATAGGACGCGGACATCCCCCGGGGTGTTACGGGTACACGGTTCGCGTGAATCCACTG  
Y R C F V G G A H N A P C A K G H L G D -  
301 TACCAACTGGGAAATTCATCTCATCTCTGTGTAATGCACTGGGGATGTCTCTGTTA 360  
ATGGTTGACCCTTTAGTAGAGTAGGACGACACTTATACGTGGAGCCCTACAGAGACAT  
Y Q L G N S H P A V N M H L G M S L L -  
361 GACAGACATGGTATGGGGGATTCATGGCTGTGCCCTCTGTGCTGTGCTGTGTGGC 420  
CTCTGTCTACCACTACCCCTTAGTACCGGACACGGGGAGAGACACAGACGACGAACCG  
E T D G D G G F M A C A P L W S R A C G -  
421 AGCTCTGTCTCAGTCTCTGGGATATGTGCCCTGTGGATGCTTCAATCCAGCCTCAGGGA 480  
TCGACAGAGAAGTCAGACCCCTATACACGGGGACACCTACGAAGTAGGTCGAGAGTCCTC

a S S V F S S S G I C A R V D A S F Q P Q G -  
AGCCTGCGACCCCATGCCCAACGCTGCCCAACATACATGGATGTTGTCATTGTCTTGGAT  
481 TCGGACCGTGGGTGACGGGTGCGACGGGTGTTATGTACCTACAACAGTAACAGAACTTA  
T C G G A C C G T G G T G A C G G G T G C G A C G G T T G T A T G T A C C T A C A A C A G T A A C A G A A C C T A

a S L A P T A Q R C P T Y M D V V I V L D -  
GGCTCCAACAGCATCTACCCCTGGTCTGAAGTTCAGACCTTCTACGAAGACTGTTAGGS  
541 CCGAGGTTGTCTAGATGGGGACCGACCTTCAAGTCTGGAAGGATGCTTCTGACCATCCC  
T C G A G G T T G T C T A G A T G G G G A C C G A C C T T C A A G T C T G G A A G A T G C T T C T G A C C A T C C C

a G S N S I Y P W S E V Q T F L R R L V G -  
AAACTGTTTATTGACCCAGAACAGATACAGGTGGGACTGGTACAGTATGGGGAGAGCCCT  
601 TTGACAAATAACTGGGTCCTTGTCTATGTCCACCTGACCATGTATACCCCTCTCGGGA  
T T T G A C A A A T A A C T G G G T C T T G T C T A T G T C C A C C T G A C C A T G T A T A C C C C T C T C G G G A

a K L F I D P E Q I Q V G L V Q Y G E S P -  
GTACATGAGTGGTCCCTGGGAGATTTCCGACGAAGGAAGAAGTGGTGAGAGCAGCAAG  
661 CATGTACTCACCAGGGACCCCTCTAAAGGCTTGCTTCCTCTTCCACCACTCTCGTGGTTTC  
G T A C A T G A G T G G T C C C T G G G A G A T T T C C G A C G A A G G A A G A A G T G G T G A G A G C A G C A A G  
C A T G T A C T C A C C A G G G A C C C T C T A A A G G C T T G C T T C C T C T T C A C C A C T C T C G T C G T T T C

a V H E W S L G D F R T K E E V V R A A K -  
AACTCAGTCCGCGGGGAGGACGAGAAACAAGACTGCCCAAGCAATATGTTGGGCTGC  
721 TTGGAGTCAGCCGCCCTCCCTGCTCTTTGTTCTGACGGGTTGTTATTAACACCGGAGC  
T T G G A G T C A G C C G C C C T C C C T G C T C T T T G T T C T G A C G G G T T C G T A T T A C C A C C G G A G C

a N L S R R R E G R E T K T A Q A I M V A C -  
ACAGAAGGGTTCAGTCAGTCCCATGGGGGCGACCGCGGCTGCCAGGCTACTGTTGGTT  
781 TGTCTCCCAAGTCAGTCAGGGAACCCCGGCTGGGCTCCGACGGTCCGATGACCACCAA  
T G T C T C C C A A G T C A G T C A G G G T A C C C C G G C T G G G C T C C G A C G G T C C G A T G A C C A C C A A

a T E G F S Q S H G G R P E A A R L L V V -  
GTCTACTGATGGAGAGTCCCATGATGGAGAGGAGCTTCTCGACGACATAAAGGCGCTGTGAG  
841 CAGTGACTACTCTCAGGGTACTACTCTCTCCGAAGGACGTCGTGATTTCCGGACACTC  
G T C T A C T G A T G G A G A G T C C C A T G A T G G A G A G G A G C T T C T C G A C G A C A T A A G G C G C T G T G A G  
C A G T G A C T A C C T C T C A G G G T A C T A C T C T C T C C G A A G G A C G T C G T G A T T C C G G A C A C T C

a V T D G E S H D G E E L P A A L K A C E -  
GCTGGAAGAGTGACACGCTATGGGATTGCAGTCTTGGTCACTACCTCCGGCGGCAGCGA  
901 CGACCTTCTCACTGTGCATACCTTAAGCTCAGGAACAGTGATGGAGGCGCGCTCGCT  
G C T G G A A G A G T G A C A C G C T A T G G G A T T G C A G T C T T G G T C A C T A C C T C C G G C G G C A G C G A  
C G A C C T T C T C A C T G T G C A T A C C T A A G C T C A G G A A C A G T G A T G G A G G C G C G C T C G C T

a A G R V C T T T R Y G I A V L G H Y L R R Q R -  
GATCCAGCTCTTTCTCGAGAGAAATAGAACTATTGCCATGATCCAGATGAGCGATTCT  
961 CTAGGGTCGAGAAAGGACTCTCTTAATCTTGATAACGCTCACTAGGCTACTCGCTAAG  
G A T C C A G C T C T T T C T C G A G A G A A A T A G A A C T A T T G C C A T G A T C C A G A T G A G C G A T T C T  
C T A G G G T C G A G A A A G G A C T C T C T T A A T C T T G A T A A C G G T C A C T A G G T C T A C T C G C T A A G

a D F S S F L R E I R T I A S D P D E R F -  
TTCCTCAATGTACAGATGAGGCTGCTCTGACTGACATSTGGATGCATAGGAGATCGG  
1021 AAGAGTTACAGTGTCTACTCCGACGAGACTGACTGTAAACCTACGTCATCTCTAGGC  
T T C T T C A A T G T A C A G A T G A G G C T G C T C T G A C T G A C A T S T G G A T G C A T A G G A G A T C G G  
A A G A G T T A C A G T G T C T A C T C C G A C G A G A C T G A C T G T A A C C T A C G T G A T C C T C T A G C C

a F F N V T D E A A L T D I V D A L G D R -  
ATTTTGGGCTTGAGAGGTCCTATGCAAGAAACGAAGCTCCTTTGGGCTGGAATGTCT  
1081 TAAAAACCGGAACCTCCGAGGGTACGCTTTTGCTTTGAGGAAACCCGACCTTTACAGA  
A T T T T T G G C T T G A G A G G T C C C A T G C A G A A A C G A A G C T C C T T T G G G C T G G A A T G T C T  
T A A A A C C G G A A C T T C C A G G G T A C G C T T T T G C T T T G A G G A A A C C G A C C T T T A C A G A

45

a I F G L E G S H A E N E S S F G L E M S -  
 CAGATTGGTTTCTCCACTCATCGGCTAAAGGATGGGATTCTTTTGGGATGGTGGGGGCC  
 1141 -----+-----+-----+-----+-----+ 1200  
 GTCTAACCAAAGAGGTGAGTAGCCGATTCTTACCCTAAGAAAAACCTACCAACCCCGG

a Q I G F S T H R L K D G I L F G M V G A -  
 TATGACTGGGGAGGCTCTGTCTATGGCTTGAAGGAGGCCACCGCTTTTCCCCACGA  
 1201 -----+-----+-----+-----+-----+ 1260  
 ATACTGACCCCTCCGAGACACGATACCGAACTTCTCGGTGGCGAAAAGGGGGGTGCT

a Y D W G G S V L W L E G G H R L F P P R -  
 ATGGCATTGGAAGACGAGTTCCCCCTGCCTGCAGAACCATGCAGCCTACCTGGGTTAC  
 1261 -----+-----+-----+-----+-----+ 1320  
 TACCGTGACCTTCTGCTCAAGGGGGGACGTGACGCTCTTGGTACGTGCGATGACCAATG

a M A L E D E F P P A L Q N H A A Y L G Y -  
 TCTGTTTCTTCCATGCTTTTGGGGGTGGACGCCGCCTGTTTCTCTGGGGCTCCTCGA  
 1321 -----+-----+-----+-----+-----+ 1380  
 AGACAAGAAGGTACGAAAACGCCACCTGCGGCGGACAAAGAGAGACCCGAGGAGCT

a S V S S M L L R G G R R L F L S G A P R -  
 TTTAGACATCGAGGAAAAGTCATGCGCTTCCAGCTTAAGAAAGATGGGCTGTGAGGGTT  
 1381 -----+-----+-----+-----+-----+ 1440  
 AAATCTAGCTCCTTTTCAGTAGCGAAGGTGCAATCTTTTACCCGACACTCCCAA

a F R H R G K V I A F Q L K K D G A V R V -  
 GCCCAGAGCCTCCAGGGGGAGCAGATTGGTTCATACTTTGGCAGTGAGCTCTGCCCATTG  
 1441 -----+-----+-----+-----+-----+ 1500  
 CGGGTCTCGGAGGTCCCCCTCGTCTAACCAAGTATGAAACCGTCACTCGAGACGGGTAAAC

a A Q S L Q G E Q I G S Y F G S E L C P L -  
 GATACAGATAGGGATGGAACAACTGATGCTTACTTGTGGCTGCCCCATGTTCTCTGGGA  
 1501 -----+-----+-----+-----+-----+ 1560  
 CTATGTCTATCCTTACCTTGTGACTACAGAATGAACCCGACGGGGGTACAAGGACCTT

a D T D R D G T T D V L L V A A P M F L G -  
 CCCCAGAACAAGGAAACAGGACGTGTTTATGTGTATCTGGTAGCCAGCAGTCTTGTCTG  
 1561 -----+-----+-----+-----+-----+ 1620  
 GGGGCTTGTTCCTTTGTCCTGCAAAATACATAGAACCATCCGCTCGTCAAGGAACGAC

a P Q N K E T G R V Y V Y L V G Q Q S L L -  
 ACCCTCCAAGGAACACTTCAGCCAGAACCCCCCAGGATGCTCGGTTTGGCTTTGCCATG  
 1621 -----+-----+-----+-----+-----+ 1680  
 TGGGAGGTTCTTGTGAAGTCGGTCTTGGGGGGTCTACGAGCCAAACCGAAACGCTAC

a T L Q G T L Q P E P P Q D A R F G F A M -  
 GGAGCTCTTCTGATCTGAACCAAGATGGTTTGTGATGTGSGCTTGGGGGCCCTCTG  
 1681 -----+-----+-----+-----+-----+ 1740  
 CCTCGAAGGACTAGACTTGGTTTACCAAAAACGACTACACCGACACCCCGCGGAGAC

a G A L P D L N Q D G F A D V A V G A P L -  
 GAAGATGGGCCACGAGGAGCACTGTACCTGTACCATGGAACCAAGAGTGGAGTCAAGGCC  
 1741 -----+-----+-----+-----+-----+ 1800  
 CTTTCAACCGTGGTCCCTCGTGACATGGACATGTTACCTTGGGTCTACCTCAGTCCGGG



46

a E D G H Q G A L Y L Y H G T Q S G V R P -  
 1801 CATCTGCCCCAGGAGATTGCTGCTGCCTCCATGCCACATGCCCTCAGTACTTTGGCCGA  
 GTAGGACGGGTCTCTAACGACGACGAGGATACGGTGTACGGAGTCGATGAACCGGCT 1860  
 a H P A Q R I A A A S M P H A L S Y F G R -  
 1861 AGTGTGGATGGTCGGCTAGATCTGGATGGAGATGATCTGGTCGATGTGGCTGTGGGTGCC  
 TCACACCTACCAACCGATCTAGACCTACCTCTACTAGACCAGCTACACCGACACCCAGG 1920  
 a S V D G R L D L D G D D L V D V A V G A -  
 1921 CAGGGGGCAGCCATCCTGCTCAGCTCCCGGCCATTGTCCATCTGACCCCATCAGTGAG  
 GTCCCCCGTCGGTAGGACGAGTCGAGGGCCGGTAAACAGGTAGACTGGGTGATGACCTC 1980  
 a Q G A A I L L S S R P I V H L T P S L E -  
 1981 GTGACCCACAGGCCATCAGTGTGGTTTACAGGGGACTGTAGGCGGCAGGCCAAGAAGCA  
 CACTGGGTGTCCGGTAGTCACACCAAGTCTCCCTGACATCCGCGCTCCGGTTCTTCGT 2040  
 a V T P Q A I S V V Q R D C R R R G Q E A -  
 2041 GTCTGTCTGACTGCAGCCCTTTGCTTCCAAGTGACCTCCCGTACTCTGGTCGTGGGAT  
 CAGACAGACTGACCTCGGAAACGAAGTTTCACTGGAGGCGATGAGGACGACGACCCCTA 2100  
 a V C L T A A L C E Q V T S R T P G R W D -  
 2101 CACCAATTCTACATGAGGTTCAACGCATCACTGGATGAATGAGTCTGGGGCAGTGCA  
 GTGGTTAAGATGTACTCCAAGTGGCGTAGTGACCTACTTACCTGACGACCCCGTGACGCT 2160  
 a H Q F Y M R F T A S L D E W T A G A R A -  
 2161 GCATTGTATGGCTCTGGCCAGAGTTGTCCCTCCGAGGCGTCGGGCTCAGTGTGGGGAA  
 CGTAAACTACGAGACCGGTCTCCAACAGGGGAGCTCCGAGGCGGAGTCACACCCCTTA 2220  
 a A F D G S G Q R L S P R R L R L S V G N -  
 2221 GTCACCTGTGAGCAGTACACTTCCATGTGCTGGATACATCAGATTACCTCCGCCCATG  
 CAGTGAACACTCGTCGATGTGAAGTACACGACCTATGTAGTCTAATGGAGGCGGTCAC 2280  
 a V T C E Q L H F H V L D T S D Y L R P V -  
 2281 GCCTTGACTGTGACCTTTGCCTTGGACAACTACTACAAAGCCAGGGCCTGTGCTGAATGAG  
 CGGAACCTGACACTGGAAACGGAACCTGTTATGATGTTTCCGTCGCCGACACGACTTACTC 2340  
 a A L T V T F A L D N T T K P G P V L N E -  
 2341 GGCTCACCACCTCTATACAAAGCTGGTCCCTTCTCAAGGATTGTGGCCCTGACAA  
 CCGAGTGGGTGGAGATATGTTTTCGACCCAGGGGAAGAGTTTCTTAACACCGGGAGCTGTTA 2400  
 a G S P T S I Q K L V P F S K D C G P D N -  
 2401 GAATGTGTACAGACCTGGTGTCTCAAGTGAATATGACATCAGAGGCTCCAGGAAGGCC  
 CTTACACAGTGTCTGGACACGAAGTCTACTTATACCTGTAGTCTCCGAGGTCTCTCCGG 2460

|      |                                                                                                                                |      |
|------|--------------------------------------------------------------------------------------------------------------------------------|------|
|      | E C V T T D L V L Q V N M D I R G S R K A -                                                                                    |      |
| 2461 | CCATTGTGGTTTCGAGGTGGCCGGCGGAAAGTCTGTGATCTACAACTCTGGAGACAGA<br>GGTAAACACCAAGCTCCACGGCGCGCTTTTCAGACCATAGATGTTGAGACCTCTGTCT       | 2520 |
| a    | P F V V R G G R R K V L V S T T L E N R -                                                                                      |      |
| 2521 | AAGGAAAATGCTTACAATACGAGCCTGAGTATCATCTTCTTAGAAACCTCCACCTGGCC<br>TTCTTTTACGAATGTTATGCTCGGACTCATAGTAGAAGAGATCTTTGGAGGTGACCGG      | 2580 |
| a    | K E N A Y N T S L S I I F S R N L H L A -                                                                                      |      |
| 2581 | AGTCTCACTCCTCAGAGAGAGAGCCCAATAAGGTGGAAATGTGCCGCCCTCTTGCTCAT<br>TCAGAGTGAGGAGTCTCTCTCTCGGTTATTTCACCTTACACGGCGGGGAAGACGAGTA      | 2640 |
| a    | S L T P Q R E S P I K V E C A A P S A H -                                                                                      |      |
| 2641 | GCCCGGCTCTGCAGTGTGGGGCATCTGTCTTCCAGACTGGAGCCAAAGTGAACCTTCTG<br>CGGGCCGAGACGTCACACCCCGTAGGACAGAAGGTCTGACCTCGGTTCCACTGGAAGAC     | 2700 |
| a    | A R L C S V G H P V F Q T G A K V T F L -                                                                                      |      |
| 2701 | CTAGAGTTTGAGTTAGCTGCTCTCTCTCTGAGCCAGGTCTTTGGGAAGCTGACTGCC<br>GATCTCAAACCTCAATCGACGAGGAGAGAGGACTCGGTCCAGAAACCTTCGACTGACGG       | 2760 |
| a    | L E F E F S C S S L L S Q V F G K L T A -                                                                                      |      |
| 2761 | AGCAGTGACAGCCTGGAGAGAAATGGCACCCCTCAAGAAAAACACAGCCAGACCTCAGCC<br>TCGTCACTCTCGGACTCTCTTTACCGTGGGAAGTCTTTTGTGTGGGTCTGGAGTCGG      | 2820 |
| a    | S S D S L E R N G T L Q E N T A Q T S A -                                                                                      |      |
| 2821 | TACATCCAATATGAGCCCCACCTCCTGTTCTCTAGTGAGTCTACCTCGACCCGCTATGAG<br>ATGTAGGTTATCTCGGGGTGGAGACAGAGATCACTCAGATGGGAGCTGGCGTACTCT      | 2880 |
| a    | Y I Q Y E P H L L F S S E S T L H R Y E -                                                                                      |      |
| 2881 | GTTCCACCATATGGGACCCCTCCAGTGGGTCTGGCCCAAGATTCAAAACCACTCTCAGG<br>CAAGTGGGTATACCTCGGGAGGGTCACCCAGGACCGGGTCTTAAGTTTTGGTGAGAGTCC    | 2940 |
| a    | V H P Y G T L P V G P G P E F K T T L R -                                                                                      |      |
| 2941 | ACTACAAATGCAAGCTTCACTAGTGCGAAGCTGACTGAACCCCAAGGCCCACTGTGCAT<br>TGATTGTGTACGTTTCGACGTATCACGCTCTTGGACTGACTTGGGGGTCCGGGTGGACACGTA | 3000 |
| a    | T N N A S C I V Q N L T E P P G P P V H -                                                                                      |      |
| 3001 | CCAGAGGAGCTTCAACACACAACAGACTGAATGGGAGCAATCACTCAGTGTTCAGTGGTG<br>GGTCTCTCGAAGTTGTGTGTTGTCTGACTTACCTCGTTATGAGTCACAGTCCACCAC      | 3060 |
| a    | P E E L Q H T N R L N G S N T Q C Q V V -                                                                                      |      |
| 3061 | AGGTGCCACCTTGGCGAGCTGGCAAGGGGACTGAGGTCTCTGTGGACTATTGAGCTG<br>TCCACGGTGGAAACCGCTCGACCGCTTCCCTGACTCCAGAGACAACTGTATAACTCCGAC      | 3120 |

48

a R C H L G Q L A K G T E V S V G L L R L -  
 3121 GTTCACAATGAATTTTTCCGAAGAGCCAAGTTCAGTCCCTGACGGTGTGTCAGCACCTTT  
 CAAGTGTTACTTAAAAAGGCTTCTCGGTCAAGTTCAGGGACTGCCACCAGTCTGGAAA 3180

a V H N E F F R R A K F K S L T V V S T F -  
 3181 GAGCTGGGAACCGAAGAGGGCAGTGTCTACAGCTGACTGAAGCCTCCCGTTGGAGTGAG  
 CTCGACCCTTGGCTTCTCCGTCACAGGATGTGCACTGACTCGGAGGGCAACCTCACTC 3240

a E L G T E E G S V L Q L T E A S R W S E -  
 3241 AGCCTCTTGGAGGTGGTTCAGACCGGCCTATCCTCATCTCCCTGTGGATCCTCATAGGC  
 TCGGAGAACCTCCACCAAGTCTGGGCGGATAGGATAGAGGGACACTAGGAGTATCCG 3300

a S L L E V V Q T R P I L I S L W I L I G -  
 3301 AGTGTCTGGGAGGGTGTCTCTGCTTGTCTCTCTGCTCTGCTGCTGGAAGCTTGGC  
 TCAGAGGACCTCCCAACGAGGACGAACGAGAGGAAGAGAGACCGACCTTCGAACCG 3360

a S V L G G L L L A L L V F C L W K L G -  
 3361 TTCTTTGCCCATAGAATAATCCCTGAGGAAGAAAAAGAGAAGAGAAGTTGGAGCAATGA  
 AAGAAACGGGTATCTTTTAGGGACTCCTTCTTTTCTCTCTCTCAACCTCGTTACT 3420

a F F A H K K I P E E E K R E E K L E Q  
 3421 ATGTAGAATAAGGGTCTAGAAAGTCTCCCTGGCAGCTTTCTTCAAGAGACTTGCATAAA  
 TACATCTTATCCAGATCTTTCAGGAGGACCGTCGAAAGAAGTCTCTGAACGTATTT 3480

3481 AGCAGAGGTTTGGGGCTCAGATGGGACAAGAAGCGCCTCTGGACTATCTCCCAGACC  
 TCGTCTCRAAACCCCGAGTCTACCTGTTCTTCGGCGGAGACCTGATAGAGGGGTCTGG 3540

3541 AGCAGCCTGACTTTGACTTTTGTGCTCCTAGGGATGCTGCTGGCTAGAGATGAGGCTTTACC  
 TCGTGGACTGAACTGAAACTCAGGATCCCTAGACGACGATCTACTCCGAAATGG 3600

3601 TCAGACAAGAAGAGCTGGCACCAAAACAGCCATGCTCCCAACCTCTGCTTCCCTCCTCC  
 AGTCTGTTCTTCTCGACCGTGGTTTTGTATCGTACGAGGGTGGGAGACGAAGGGAGGAGG 3660

3661 TCGTATCCTGTTCCATAGCCAACTGGGGCTTTTGTGTTGGGGTCTTTTATCCCCAG  
 AGCACTAGGACCAAGTATCGGTTGTGACCCCGAAAAACAACCCAGGAAAAATAGGGGTC 3720

3721 GAATCAATAATTTTTTGCCTAGGAAAAAAAAGCGCCGCGAATTCGATATCAAGCT  
 CTTAGTTATTAATAAACGATCCTTTTTTTTTTCGCCGGCGCTTAAGCTATAGTTCTGA 3779

49

## (2) INFORMATION FOR SEQ ID NO. 3:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 143 base pairs  
 (B) TYPE: nucleic acid and amino acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear
- (iii) MOLECULAR TYPE: cDNA
- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: human  
 (B) CELLTYPE: chondrocyte
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO. 3:

NdeI

1 GGGGCATATGGTTCAGAACCTGGGTTGCTACGTTGTTCCGGTCTGATCATCTCCGCTCT  
 -----+----- 60  
 CCCCGTATACCAAGTCTTGGACCCAAACGATGCAACAAAGGCCAGACTAGTAGAGGCGAGA

b G H M V Q N L G C Y V V S G L I I S A L -  
 GGTGCCGGCTGTGCTCACGGTGGTAACCTACTTCCTAAGCTTGTCCAGGTTATCAGCGG  
 61 -----+----- 120  
 CGACGCGCGACACGAGTGCCACCATTGATGAAGGATTCGAACAGGGTCCAATAGTCGCC

b L P A V A H G G N Y F L S L S Q V I S G -

BamHI

121 CCTGGTGCGCGCGGATCCCCC  
 -----+----- 143  
 GGACCACGCGCGCCTAGGGGGG

b L V P R G S P -

ATT 24 AND 1

CLAIMS

1. A recombinant or isolated collagen binding  
integrin subunit  $\alpha 10$  comprising essentially the amino  
5 acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or  
homologues or fragments thereof having essentially the  
same biological activity.

2. A process of producing a recombinant integrin  
subunit  $\alpha 10$  comprising essentially the amino acid  
10 sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or  
homologues or fragments thereof having essentially the  
same biological activity, which process comprises the  
steps of

a) isolating a polynucleotide comprising a nucleo-  
15 tide sequence coding for an integrin subunit  $\alpha 10$ , or  
homologues or fragments thereof having essentially the  
same biological activity,

b) constructing an expression vector comprising the  
isolated polynucleotide,

20 c) transforming a host cell with said expression  
vector,

d) culturing said transformed host cell in a culture  
medium under conditions suitable for expression of inte-  
grin subunit  $\alpha 10$ , or homologues or fragments thereof hav-  
25 ing essentially the same biological activity, in said  
transformed host cell, and, optionally,

e) isolating the integrin subunit  $\alpha 10$ , or homologues  
or fragments thereof having essentially the same  
biological activity, from said transformed host cell or  
30 said culture medium.

3. A process of providing an integrin subunit  $\alpha 10$ ,  
or homologues or fragments thereof having essentially the  
same biological activity, whereby said subunit is  
isolated from a cell in which it is naturally present.

35 4. An isolated polynucleotide comprising a nucleo-  
tide coding for an integrin subunit  $\alpha 10$ , or for homolo-  
gues or fragments thereof having essentially the same

29 -05- 2000

51

biological activity, which polynucleotide comprises essentially the nucleotide sequence shown in SEQ ID No. 1 or SEQ ID No. 2 or suitable parts thereof.

5 An isolated polynucleotide or oligonucleotide which hybridises to a DNA or RNA coding for an integrin subunit  $\alpha 10$ , or for homologues or fragments thereof having essentially the same biological activity, wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  
10  $\alpha 1$ .

6 A vector comprising a polynucleotide or oligonucleotide coding for an integrin subunit  $\alpha 10$ , or for homologues or fragments thereof having essentially the same biological activity, which polynucleotide or oligonucleotide comprises essentially the nucleotide  
15 sequence shown in SEQ ID No. 1 or SEQ ID No. 2 or parts thereof.

7 A vector comprising a polynucleotide or oligonucleotide which hybridises to a DNA or RNA coding for an integrin subunit  $\alpha 10$ , or for homologues or fragments  
20 thereof, wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ .

8 A cell containing the vector as defined in any  
25 one of claims 6 and 7.

9 A cell generated by steps a) to d) of the process as defined in claim 2, in which a polynucleotide or oligonucleotide coding for an integrin subunit  $\alpha 10$ , or for homologues or fragments thereof having essentially  
30 the same biological activity, which polynucleotide or oligonucleotide comprises the nucleotide sequence shown in SEQ ID No. 1 or SEQ ID No. 2 or parts thereof, has been stably integrated in the cell genome.

10 Binding entities having the capability of binding specifically to an integrin subunit  $\alpha 10$  comprising  
35 the amino acid sequence of SEQ ID No. 1 or SEQ ID No. 2, or to homologues or fragments thereof.

AMENDED SHEET

29 -05- 2000

11. Binding entities according to claim 10, which are chosen from the group comprising proteins, peptides, carbohydrates, lipids, natural integrin binding ligands, and fragments thereof.

5 12. Binding entities according to claim 10, which are polyclonal or monoclonal antibodies, or fragments thereof.

13. A recombinant or isolated integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , in which the  
10 subunit  $\alpha 10$  comprises essentially the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, and homologues and fragments thereof having essentially the same biological activity.

14. A recombinant or isolated integrin heterodimer  
15 according to claim 13, wherein the subunit  $\beta$  is  $\beta 1$ .

15. A process of producing a recombinant integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , in which the subunit  $\alpha 10$  comprises essentially the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, and  
20 homologues and fragments thereof having essentially the same biological activity, which process comprises the steps of

a) isolating one polynucleotide comprising a nucleotide sequence coding for a subunit  $\alpha 10$  of an integrin  
25 heterodimer and, optionally, another polynucleotide comprising a nucleotide sequence coding for a subunit  $\beta$  of an integrin heterodimer, or polynucleotides or oligonucleotides coding for homologues or fragments thereof having essentially the same biological activity,

30 b) constructing an expression vector comprising said isolated polynucleotide coding for said subunit  $\alpha 10$  optionally in combination with an expression vector comprising said isolated nucleotide coding for said subunit  $\beta$ ,

35 c) transforming a host cell with said expression vector or vectors,

d) culturing said transformed host cell in a culture medium under conditions suitable for expression of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or homologues or fragments thereof having essentially the same biological activity, in said transformed host cell, and, optionally,

e) isolating the integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or homologues or fragments thereof having essentially the same biological activity, or the  $\alpha 10$  subunit thereof from said transformed host cell or said culture medium.

16. A process of providing a integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or homologues or fragments thereof having essentially the same biological activity, whereby said integrin heterodimer is isolated from a cell in which it is naturally present.

17. A cell containing a first vector, said first vector comprising a polynucleotide or oligonucleotide coding for a subunit  $\alpha 10$  of an integrin heterodimer, or for homologues or parts thereof having essentially the same biological activity, which polynucleotide or oligonucleotide comprises essentially the nucleotide sequence shown in SEQ ID No. 1 or SEQ ID No. 2 or parts thereof, and a second vector, said second vector comprising a polynucleotide or oligonucleotide coding for a subunit  $\beta$  of an integrin heterodimer, or for homologues or fragments thereof having essentially the same biological activity.

18. Binding entities having the capability of binding specifically to an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having essentially the same biological activity, or an subunit  $\alpha 10$  thereof, having essentially the same biological activity.

19. Binding entities according to claim 18, wherein the subunit  $\beta$  is  $\beta 1$ .



29 -05- 2000

54

20. Binding entities according to claim 18 or 19, which are chosen among the group comprising proteins, peptides, carbohydrates, lipids, natural integrin binding ligands, and fragments thereof.

21. Binding entities according to claim 18 or 19, which are polyclonal or monoclonal antibodies

22. A fragment of the integrin subunit  $\alpha 10$ , which fragment is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain.

23. A fragment according to claim 22, which is a peptide comprising the amino acid sequence  
KLGFFAHKKIPEEEKREEKLEQ.

24. A fragment according to claim 22, which comprises the amino acid sequence from about amino acid No. 952 to about amino acid no. 986 of SEQ ID No. 1.

25. A fragment according to claim 22, which is a peptide comprising the amino acid sequence from about amino acid No. 140 to about amino acid no. 337 of SEQ ID No. 1.

26. A method of producing a fragment of the integrin subunit  $\alpha 10$  as defined in any one of claims 22-25, which method comprises a sequential addition of amino acids containing protective groups.

27. A polynucleotide or oligonucleotide coding for a fragment of the integrin subunit  $\alpha 10$  as defined in any one of claims 22-25.

28. Binding entities having the capability of binding specifically to a fragment of the human integrin subunit  $\alpha 10$  as defined in any one of claims 22-25.

29. Binding entities according to claim 28, which are chosen from the group comprising proteins, peptides, carbohydrates, lipids, natural integrin binding ligands, and fragments thereof.

30. Binding entities according to claim 28, which are polyclonal or monoclonal antibodies, or fragments thereof.

AMENDED SHEET

29 -05- 2000

55

31. An *in vitro* process of using an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or a  
5 homologue or fragment of said integrin or subunit having essentially the same biological activity, as a marker or target molecule of cells or tissues expressing said integrin subunit  $\alpha 10$ , which cells or tissues are of animal including human origin.

10 32. An *in vitro* process according to claim 31, whereby said fragment is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain.

33. An *in vitro* process according to claim 31,  
15 whereby said fragment is a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ.

34. An *in vitro* process according to claim 31,  
whereby said fragment comprises the amino acid sequence from about amino acid no. 952 to about amino acid no. 986  
20 of SEQ ID No. 1.

35. An *in vitro* process according to claim 31,  
whereby said fragment comprises the amino acid sequence from about amino acid no. 140 to about amino acid no. 337  
of SEQ ID No. 1.

36. An *in vitro* process according to claim 31,  
whereby the subunit  $\beta$  is  $\beta 1$ .

37. An *in vitro* process according to claim 31,  
whereby said cells are chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells,  
30 osteoblasts and fibroblasts.

38. An *in vitro* process according to any one of claims 31-37, which process is used during pathological conditions involving said subunit  $\alpha 10$ .

39. An *in vitro* process according to claim 38, which  
35 pathological conditions comprise damage of cartilage.

AMENDED SHEET

29 -05- 2000

40. An *in vitro* process according to claim 38, which pathological conditions comprise trauma, rheumatoid arthritis and osteoarthritis.

41. An *in vitro* process according to any one of  
5 claims 31-37, which is a process for detecting the formation of cartilage during embryonal development.

42. An *in vitro* process according to any one of claims 31-37, which is a process for detecting physiological or therapeutic reparation of cartilage.

43. An *in vitro* process according to any one of  
10 claims 31-37, which is a process for selection and analysis, or for sorting, isolating or purification of chondrocytes.

44. An *in vitro* process according to any one of  
15 claims 31-37, which is a process for detecting regeneration of cartilage or chondrocytes during transplantation of cartilage or chondrocytes.

45. A process according to any one of claims 31-37,  
20 which is a process for *in vitro* studies of differentiation of chondrocytes.

46. An *in vitro* process of using binding entities  
having the capability of binding specifically to an  
integrin subunit  $\alpha 10$  comprising the amino acid sequence  
shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin  
25 heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ ,  
or to homologues or fragments thereof having essentially  
the same biological activity, as markers or target  
molecules of cells or tissues expressing said integrin  
subunit  $\alpha 10$ , which cells or tissues are of animal  
30 including human origin.

47. An *in vitro* process according to claim 46,  
whereby said fragment is a peptide chosen from the group  
comprising peptides of the cytoplasmic domain, the I-  
domain and the spliced domain.

48. An *in vitro* process according to claim 46,  
35 whereby said fragment is a peptide comprising the amino  
acid sequence KLGFFAHKKIPEEEEKREEKLEQ.

29 -05- 2000

57

49. An *in vitro* process according to claim 46, whereby said fragment comprises the amino acid sequence from about amino acid no. 952 to about amino acid no. 986 of SEQ ID No. 1.

50. An *in vitro* process according to claim 46, whereby said fragment comprises the amino acid sequence from about amino acid no. 140 to about amino acid No. 337 of SEQ ID No. 1.

51. An *in vitro* process according to claim 46, whereby the subunit  $\beta$  is  $\beta 1$ .

52. An *in vitro* process according to any one of claims 46-51, which is a process for detecting the presence of an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or of an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or of homologues or fragments thereof having essentially the same biological activity.

53. An *in vitro* process according to any one of claims 46-51, which process is a process for determining the differentiation-state of cells during embryonic development, angiogenesis, or development of cancer.

54. An *in vitro* process for detecting the presence of a integrin subunit  $\alpha 10$ , or of a homologue or fragment of said integrin subunit having essentially the same biological activity, on cells, whereby a polynucleotide or oligonucleotide chosen from the group comprising a polynucleotide or oligonucleotide shown in SEQ ID No. 1 is used as a marker under hybridisation conditions wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ .

55. An *in vitro* process according to claim 54, whereby said cells are chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

56. An *in vitro* process according to claim 54, whereby said fragment is a peptide chosen from the group

AMENDED SHEET

comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain.

57. An *in vitro* process according to claim 54, whereby said fragment is a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ.

58. An *in vitro* process according to claim 54, whereby said fragment comprises the amino acid sequence from about amino acid No. 952 to about amino acid no. 986 of SEQ ID No. 1.

59. An *in vitro* process according to claim 54, whereby said fragment comprises the amino acid sequence from about amino acid No. 140 to about amino acid No. 337 of SEQ ID No. 1.

60. An *in vitro* process according to any one of claims 54-59, which is a process for determining the differentiation-state of cells during development, in pathological conditions, in tissue regeneration or in therapeutic and physiological reparation of cartilage.

61. An *in vitro* process according to claim 60, wherein the pathological conditions are any pathological conditions involving the integrin subunit  $\alpha 10$ .

62. An *in vitro* process according to claim 61, whereby said pathological conditions are rheumatoid arthritis, osteoarthritis or cancer.

63. An *in vitro* process according to claim 60, whereby said cells are chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

64. An *in vitro* process for determining the differentiation-state of cells during development, in pathological conditions, in tissue regeneration and in therapeutic and physiological reparation of cartilage, whereby a polynucleotide or oligonucleotide chosen from the nucleotide sequence shown in SEQ ID No. 1 is used as a marker under hybridisation conditions wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ .

29 -05- 2000

59

65. An *in vitro* process according to claim 64,  
whereby said polynucleotide or oligonucleotide is a  
polynucleotide or oligonucleotide coding for a peptide  
chosen from the group comprising peptides of the  
5 cytoplasmic domain, the I-domain and the spliced domain.

66. An *in vitro* process according to claim 65,  
whereby said polynucleotide or oligonucleotide is a  
polynucleotide or oligonucleotide coding for a peptide  
comprising the amino acid sequence  
10 KLGFFAHKKIPEEEKREEKLEQ.

67. An *in vitro* process according to claim 65,  
whereby said peptide comprises the amino acid sequence  
from about amino acid no. 952 to about amino acid no. 986  
of SEQ ID No. 1.

68. An *in vitro* process according to claim 65,  
whereby said peptide comprises the amino acid sequence  
from about amino acid no. 140 to about amino acid no. 337  
of SEQ ID No. 1.

69. An *in vitro* process according to claim 65,  
whereby said pathological conditions are any pathological  
conditions involving the integrin subunit  $\alpha 10$ .

70. An *in vitro* process according to claim 69,  
whereby said pathological conditions are rheumatoid  
arthritis, osteoarthritis or cancer.

71. An *in vitro* process according to claim 69,  
whereby said pathological conditions are atherosclerosis  
or inflammation.

72. An *in vitro* process according to any one of  
claims 64-71, whereby said cells are chosen from the  
30 group comprising chondrocytes, smooth muscle cells,  
endothelial cells, osteoblasts and fibroblasts.

73. A pharmaceutical composition comprising as an  
active ingredient a pharmaceutical agent or an antibody  
which is capable of using an integrin heterodimer com-  
prising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$   
35 thereof, or a homologue or fragment of said integrin or

AMENDED SHEET

subunit  $\alpha 10$  having essentially the same biological activity, as a target molecule.

74. A pharmaceutical composition according to claim 73, for use in stimulating, inhibiting or blocking the formation of cartilage, bone or blood vessels.

75. A pharmaceutical composition according to claim 73, for use in preventing adhesion between tendon/ligaments and the surrounding tissue after infection, inflammation and after surgical intervention where adhesion impairs the function of the tissue.

76. A vaccine comprising as an active ingredient an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$ , or DNA or RNA coding for said integrin subunit  $\alpha 10$ .

77. *In vitro* use of the integrin subunit  $\alpha 10$  as a marker or target in transplantation of cartilage or chondrocytes.

78. An *in vitro* method of using binding entities having the capability of binding specifically to an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having essentially the same biological activity, for promoting adhesion of chondrocytes and/or osteoblasts to surfaces of implants to stimulate osseointegration.

79. A method of *in vitro* detecting the presence of integrin binding entities, comprising interaction of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit having essentially the same biological activity, with a sample, thereby causing said integrin, subunit  $\alpha 10$ , or homologue or fragment thereof, to modulate the binding to its natural ligand or other integrin binding proteins present in said sample.

29 -05- 2000

61

80. A method of *in vitro* studying consequences of the interaction of a human heterodimer integrin comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit having essentially the same biological activity, with an integrin binding entity and thereby initiate a cellular reaction.

81. A method according to claim 80, whereby the consequences of said interactions are measured as alterations in cellular functions.

82. An *in vitro* method of using DNA or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof as a target molecule.

83. An *in vitro* method according to claim 82, whereby a polynucleotide or oligonucleotide hybridises to the DNA or RNA encoding an integrin subunit  $\alpha 10$ , or homologues or fragments thereof having essentially the same biological activity, and whereby said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ .

84. An *in vitro* method of using a human heterodimer integrin comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit, or a DNA or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof, as a marker or target molecule during angiogenesis.

85. A pharmaceutical composition comprising as an active ingredient a pharmaceutical agent or an antibody which is capable of stimulating cell surface expression of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$  having essentially the same biological activity.

86. A process of using a collagen binding integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or a

AMENDED SHEET



homologue or fragment of said integrin or subunit having essentially the same biologically activity, as a marker or target molecule of cells or tissues expressing said integrin subunit  $\alpha 10$ , which cells or tissues are of animal including human origin.

87. A process according to claim 86, whereby said fragment is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain.

88. A process according to claim 86, whereby said fragment is a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREBKLEQ.

89. A process according to claim 86, whereby said fragment comprises the amino acid sequence from about amino acid no. 952 to about amino acid no. 986 of SEQ ID No. 1.

90. A process according to claim 86, whereby said fragment comprises the amino acid sequence from about amino acid no. 140 to about amino acid no. 337 of SEQ ID No. 1.

91. A process according to claim 86, whereby the subunit  $\beta$  is  $\beta 1$ .

92. A process according to claim 86, whereby said cells are chosen from the group comprising chondrocytes, smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

93. A process according to any one of claims 86-92, which process is used during pathological conditions involving said subunit  $\alpha 10$ .

94. A process according to claim 93, which pathological conditions comprise damage of cartilage.

95. A process according to claim 93, which pathological conditions comprise trauma, rheumatoid arthritis and osteoarthritis.

96. A process according to any one of claims 86-92, which is a process for detecting the formation of cartilage during embryonal development.

29 -05- 2000

63

97. A process according to any one of claims 86-92, which is a process for detecting physiological or therapeutic repairation of cartilage.

98. A process according to any one of claims 86-92, which is a process for detecting regeneration of cartilage or chondrocytes during transplantation of cartilage or chondrocytes.

99. A process of using binding entities having the capability of binding specifically to an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having essentially the same activity, as markers or target molecules of cells or tissues expressing said integrin subunit  $\alpha 10$ , which cells or tissues are of animal including human origin.

100. A process according to claim 99, whereby said fragment is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the spliced domain.

101. A process according to claim 99, whereby said fragment is a peptide comprising the amino acid sequence KLGFFAHKKIPEEEKREEKLEQ.

102. A process according to claim 99, whereby said fragment comprises the amino acid sequence from about amino acid no. 952 to about amino acid no. 986 of SEQ ID No. 1.

103. A process according to claim 99, whereby said fragment comprises the amino acid sequence from about amino acid no. 140 to about amino acid No. 337 of SEQ ID No. 1.

104. A process according to claim 99, whereby the subunit  $\beta$  is  $\beta 1$ .

105. A process according to any one of claims 99-104, which is a process for detecting the presence of an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or of an integrin

AMENDED SHEET

29 -05- 2000

64

heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or of homologues or fragments thereof having essentially the same biological activity.

106. A process according to any one of claims 99-  
5 104, which process is a process for determining the differentiation-state of cells during embryonic development, angiogenesis, or development of cancer.

107. A process for detecting the presence of an integrin subunit  $\alpha 10$ , or of a homologue or fragment of  
10 said integrin subunit having essentially the same activity, on cells, whereby a polynucleotide or oligonucleotide chosen from the group comprising a polynucleotide or oligonucleotide shown in SEQ ID No. 1 is used as a marker under hybridisation conditions  
15 wherein said polynucleotide or oligonucleotide fails to hybridise to a DNA or RNA encoding an integrin subunit  $\alpha 1$ .

108. A process according to claim 107, whereby said cells are chosen from the group comprising chondrocytes,  
20 smooth muscle cells, endothelial cells, osteoblasts and fibroblasts.

109. A process according to claim 107, whereby said fragment is a peptide chosen from the group comprising peptides of the cytoplasmic domain, the I-domain and the  
25 spliced domain.

110. A process according to claim 107, whereby said fragment is a peptide comprising the amino acid sequence  
KLGFFAHKKIPEEEKREEKLEQ.

111. A process according to claim 107, whereby said  
30 fragment comprises the amino acid sequence from about amino acid No. 952 to about amino acid no. 986 of SEQ ID No. 1.

112. A process according to claim 107, whereby said fragment comprises the amino acid sequence from about  
35 amino acid No. 140 to about amino acid No. 337 of SEQ ID No. 1.

AMENDED SHEET

113. A process according to any one of claims 107-  
112, which is a process for determining the  
differentiation-state of cells during development, in  
pathological conditions, in tissue regeneration or in  
5 therapeutic and physiological reparation of cartilage.

114. A process according to claim 113, wherein the  
pathological conditions are any pathological conditions  
involving the integrin subunit  $\alpha 10$ .

115. A process according to claim 113, whereby said  
10 pathological conditions are rheumatoid arthritis, osteo-  
arthrosis or cancer.

116. A process according to claim 113, whereby said  
cells are chosen from the group comprising chondrocytes,  
smooth muscle cells, endothelial cells, osteoblasts and  
15 fibroblasts.

117. A process for determining the differentiation-  
state of cells during development, in pathological con-  
ditions, in tissue regeneration and in therapeutic and  
physiological reparation of cartilage, whereby a poly-  
20 nucleotide or oligonucleotide chosen from the nucleotide  
sequence shown in SEQ ID No. 1 is used as a marker under  
hybridisation conditions wherein said polynucleotide or  
oligonucleotide fails to hybridise to a DNA or RNA encod-  
ing an integrin subunit  $\alpha 1$ .

118. A process according to claim 117, whereby said  
polynucleotide or oligonucleotide is a polynucleotide or  
oligonucleotide coding for a peptide chosen from the  
group comprising peptides of the cytoplasmic domain, the  
I-domain and the spliced domain.

119. A process according to claim 117, whereby said  
polynucleotide or oligonucleotide is a polynucleotide or  
oligonucleotide coding for a peptide comprising the amino  
acid sequence KLGFFAHKKIPEEEKREEKLEQ.

120. A process according to claim 117, whereby said  
35 polynucleotide or oligonucleotide is a polynucleotide or  
oligonucleotide coding for a peptide comprising the amino

29-05-2000

66

acid sequence from about amino acid no. 952 to about amino acid no. 986 of SEQ ID No. 1.

121. A process according to claim 117, whereby said polynucleotide or oligonucleotide is a polynucleotide or  
5 oligonucleotide coding for a peptide comprising the amino acid sequence from about amino acid no. 140 to about amino acid no. 337 of SEQ ID No. 1.

122. A process according to claim 117, whereby said pathological conditions are any pathological conditions  
10 involving the integrin subunit  $\alpha 10$ .

123. A process according to claim 117, whereby said pathological conditions are rheumatoid arthritis, osteo-arthrosis or cancer.

124. A process according to claim 117, whereby said  
15 pathological conditions are atherosclerosis or inflammation.

125. A process according to any one of claims 117-124, whereby said cells are chosen from the group comprising chondrocytes, smooth muscle cells, endothelial  
20 cells, osteoblasts and fibroblasts.

126. A method of using an integrin subunit  $\alpha 10$  as defined in claim 1 as a marker or target in transplantation of cartilage or chondrocytes.

127. A method of using binding entities having the  
25 capability of binding specifically to an integrin subunit  $\alpha 10$  comprising the amino acid sequence shown in SEQ ID No. 1 or SEQ ID No. 2, or an integrin heterodimer comprising said subunit  $\alpha 10$  and a subunit  $\beta$ , or to homologues or fragments thereof having essentially the same  
30 biological activity, for promoting adhesion of chondrocytes and/or osteoblasts to surfaces of implants to stimulate osseointegration.

128. Use of an integrin heterodimer comprising an integrin subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$   
35 thereof, or a homologue or fragment of said integrin or subunit  $\alpha 10$  having essentially the same biological activity, as a target for anti-adhesive drugs or

AMENDED SHEET

molecules in tendon, ligament, skeletal muscle or other tissues where adhesion impairs the function of the tissue.

129. A method of stimulating, inhibiting or blocking  
5 the formation of cartilage or bone, comprising administration to a subject a suitable amount of a pharmaceutical agent or an antibody which is capable of using an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or  
10 fragment of said integrin or subunit  $\alpha 10$  having essentially the same biological activity, as a target molecule.

130. A method of preventing adhesion between tendon/ligaments and the surrounding tissue after infection,  
15 inflammation and after surgical intervention where adhesion impairs the function of the tissue, comprising administration to a subject a suitable amount of a pharmaceutical agent or an antibody which is capable of using an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  $\alpha 10$  thereof, or a homologue or  
20 fragment of said integrin or subunit  $\alpha 10$  having essentially the same biological activity, as a target molecule.

131. A method of stimulating extracellular matrix  
25 synthesis and repair by activation or blockage of an integrin heterodimer comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or of the subunit  $\alpha 10$  thereof, or of a homologue or fragment of said integrin or subunit  $\alpha 10$  having essentially the same biological activity.

132. A method of using DNA or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof as  
30 a target molecule.

133. A method according to claim 132, whereby a polynucleotide or oligonucleotide hybridises to the DNA  
35 or RNA encoding an integrin subunit  $\alpha 10$  or homologues or fragments thereof and whereby said polynucleotide or oli-

gonucleotide fails to hybridise to a DNA or RNA encoding  
an integrin subunit  $\alpha 1$ .

134. A method of using a human heterodimer integrin  
comprising a subunit  $\alpha 10$  and a subunit  $\beta$ , or the subunit  
5  $\alpha 10$  thereof, or a homologue or fragment of said integrin  
or subunit having essentially the same biological  
activity, or a DNA or RNA encoding an integrin subunit  
 $\alpha 10$  or homologues or fragments thereof, as a marker or  
target molecule during angiogenesis.

10

AMENDED SHEET

1/22




FIGURE 1



2/22

| Peptide | Amino acid sequence |
|---------|---------------------|
| 1       | DNTAQTSA YIQYEPHHSI |
| 2       | GPGHWDR             |
| 3       | AAFDGSGQR           |
| 4       | FAMGALPD            |
| 5       | FTASLDEWTTAAR       |
| 6       | VDASFRPQGXLAP       |

FIGURE 2

3/22




FIGURE 3

4/22




FIGURE 4

5/22




FIGURE 5



7/22





FIGURE 7

8/22



**B** IP:  $\alpha 10$   $\beta 1$   
 Blot:  $\beta 1$   $\beta 1$




FIGURE 8

9/22




FIGURE 9



10/22





FIGURE 10

11/22



12/22

**Human RNA Master blot**

| Tissue          | $\alpha 10$ expression | Tissue               | $\alpha 10$ expression |
|-----------------|------------------------|----------------------|------------------------|
| Aorta           | ++++                   | Thyroid gland        | -                      |
| Trachea         | +                      | Salivary gland       | -                      |
| Lung            | ++                     | Spleen               | -                      |
| Fetal lung      | ++                     | Fetal spleen         | -                      |
| Kidney          | ++                     | Thymus               | -                      |
| Fetal kidney    | (+)                    | Fetal thymus         | -                      |
| Heart           | (+)                    | Peripheral leucocyte | -                      |
| Fetal heart     | ++                     | Lymph node           | -                      |
| Spinal cord     | ++                     | Appendix             | -                      |
| Mammary gland   | (+)                    | Placenta             | -                      |
| Bone marrow     | (+)                    | Whole brain          | -                      |
| Small intestine | (+)                    | Fetal brain          | -                      |
| Skeletal muscle | -                      | Amygdala             | -                      |
| Liver           | -                      | Caudate nucleus      | -                      |
| Fetal liver     | -                      | Cerebellum           | -                      |
| Colon           | -                      | Cerebral cortex      | -                      |
| Bladder         | -                      | Frontal lobe         | -                      |
| Uterus          | -                      | Hippocampus          | -                      |
| Prostate        | -                      | Medulla oblongata    | -                      |
| Stomach         | -                      | Occipital lobe       | -                      |
| Testis          | -                      | Putamen              | -                      |
| Ovary           | -                      | Substantia nigra     | -                      |
| Pancreas        | -                      | Temporal lobe        | -                      |
| Pituitary gland | -                      | Thalamus             | -                      |
| Adrenal gland   | -                      | Subthalamic nucleus  | -                      |

FIGURE 12

13/22




FIGURE 13

14/22




FIGURE 14

[illegible]

FIGURE 15a

16/22

[illegible]

FIGURE 15b

17/22

CAGGTGGAGGGAAGCAAACTTGGTTTCTGCTGGGAATGGAGTTATGTGGATTGTATATAATTGGGACATTATGGCTAAA 2800  
 R . G K Q T W F L L G M E V M W I V Y N W D H V G .  
 L G E G E S K L G F C G E W E W K L C G L F I I G T I M A K  
 U V B R E A N L V S A G H G S Y V D C L . L G P L M W L K  
 ATCTYGGCGGCTCAGGTGGAGGTTAATACCGATGCTATATTCCTGTGGCACTCATGTCTTAGACACCCAAATGG 2880  
 N L A G A G L O V G G . Y R C Y I S C V H S C S . T P K W  
 I ? R A A L R S E T D A I F P V C T H A L R H P N G  
 S ? C R S G R R L I P M L Y F L C A L M F L D T Q N  
 CAGTGGC'CAAAACTTGGCTTGTACCTCATTATCTAAACCTTTGTACCTAATATCAAAACCTTGGCTCAAACT 2960  
 O W P K L P L A C T S L S K P L Y L I I . N L G P K L  
 S G G Q N F L W L V P H Y L N L C T . L S K T L V L N  
 A V A K T S S G L Y L I I . T F V P N Y L V P L W S . T  
 CCACAGACATGAGGCGACAGAAAAGAGAGCTGTCTCTCATCTTCCATTG30TTACATGATTCTCAGCTTCCCTGCTTCT 3040  
 H R R H E G T O E K R R V S H L P F G Y T D S Y L P C F  
 S T D M B A R Q K E R D V S L I F H S V T L I P T P F A S  
 P Q T . G H R K E T C L S S S I R L H . F L P S L L L  
 CCTGCCATTGGTCTTGGTGCTGAGGCAATAATGCTTACTATGTGTCAGAACTCGGGTTCCCTTAAGACAGCG 3120  
 L S P L V L L G A . G I I A L L C G Q N S G F A . R P  
 P C H N W C S L V P R A . L P Y Y V V R T L G S P N D R  
 P A I G A P W C L R H N C L T M W S E L W V R L T T  
 AGCTACAGTCTTGGTCTCTATAGCGCTGCCAAITTCCTGGATTAAAAAAAAGGCTCACATATAAAATCTTTCTGA 3200  
 S . S T P S H S R S P A N F L D K K K A H I . N T P S E  
 A T V S G L I A L L P T S W I K K R L C T Y F K I P L  
 E L O F L V S . P C O F P P O L K K F V G S H I K Y L F .  
 AAATGAGCAGCATGTGAGTGAAGTTAGAITTTGGGGGATGGAGGGTCTTGAGTCAAGAGCAGAGACATAGAGAG 3280  
 N E H S V S . S . I L G D G G G L L G C K E Q D S R E  
 K M S T V V S V R W G H E G C L D A K S K T V E K  
 K . A O C E I K L D F G G W M V A M Q R A R Q . R R  
 AGAATCATGGAGGGATAGAGGGCTGGAAITTTTCCCTGCTAGTGGCTATAATCTTCTTCTTAAATAACAGCTCTG 3360  
 E N H O R D R K R L K E F P P S A L . S L F P K I T A L  
 R I N G G I R G H F S L L V P Y N L C F L K Q L R  
 E S W E G . E A G I F P C . C P I I F V S . N N S S  
 ATTTTATGGGAATTGGGCTCAGGAGAAGGAATCAGTAGGCACAGATGGGACCCAGCGTGAGCTAAAGTTTATAGGAAA 3440  
 I L W E L G S G E P N O . A Q M G P Q A W T K V . G N  
 P Y G N W G Q E K O I S R R H R W D P K R G L K F R E K  
 D F N G I G V R R K E S V O T D T P S V D . S L R E  
 CTATGGGATAGGCAAGGGTGTTTTGAAGTGGATGAGATGAGGAGATTGTGTGGGGGGGAUTCTTGGGGTGATAGG 3520  
 Y G S R Q G V F V R W H R . G D C G G G S E S W G .  
 T M O V G K G C L . G G H R . D E E I V V G G S L G Q D R  
 L W E . A R G V C K V D E M A R L L W W G G V L G V I G  
 ACCTTAACAGGATAGTGGAACTGTGTGGGAGGCGGTGGTTCCACCCACTTAATTAGCGTTGAGTTGGAG 3600  
 D P . Q G M A N C V W A G R W F H P L N . R . G W G  
 T L N R I R W C T V G G G R G V S T H L I S E V E V G R  
 P L T G I D O K L C G R F E V L P T L A L R L  
 GGTGGGAAGAGCCAGCATCTCAACTTTGGAGAAGTGCAGTGTGGAAGAAGAAACAGAAAGAGGAGACCCCGGC 3680  
 G W K E P A L S T L E K V O V Q E E T E R G D T P A  
 A G R S O H Z O P W R K C K C D M K K K O K E S E P L  
 G L E G A S T L N L G E S A S V T R A N R K R R N P G  
 AGGAGCTCTTGGCTGTCTTCCATCGCCCTGGCTTTGGAGAAGATAGGAAGGGTGGTGACTCTGACTCTCTCA 3760  
 G S S L P S F L P M A L A L G R I R K G W . L C I L  
 Q G A L F H R I F S H G P G F E G K L . E R V V S A H S  
 R E L L A I V S S H G P G F E G K L . E R V V S A H S  
 GAAAGCCCTCTCTCCCTTTGGACTCTCGAGCTTAGAGAGGAGAATGTAGAGGGAATGATGTGGAAAGAGTAAT 3840  
 R K A L S P S L D S R G L E R R N C R N R D V E R V L  
 T E K P S L P L W T L E A . R G E C V G G H M W E T L  
 K S P L S L F G L S L R E E N V . E E . C O K S N  
 TGACTATCCAGATGTGTGTAATGAGATTCAAGGAATGAGAAATACAGCTGTGCTTCAAGCATGGCGGAGGCG 3920  
 P . P I O H C L M R R Q E . E W K Y S C A S A W P R A  
 D L S R C V C E D P V N T A V L G L Q H A G R G  
 L T Y P D V S V N E I S G H R M B I Q L C F S H A E G  
 CTTAGATCCTCAACCCACCCACAGGAAGAAATCAATCAATCACTCCAGCTGGGTTCTGAGGACATGACATGAC 4000  
 L G S L T P T P O E E N H P I I P P G V L R T . H .  
 P L R I F P H P T T G R E S S N H P T W G S E D M T L T  
 ACAGAGCAGAGACTGAGATGAAACACTCCCTCTGTCTTGTCTCCCATTAAGCTCACCAGTCTCTCAATTAAGTGT 4080  
 H R A G E L K R S L S L S L S L P L S L S T S P L S T D  
 T E Q S S . D R N T P S C L V S C L F H L I  
 T S R R A E I E T L P P V L S P T K P N O S F I N .

FIGURE 15c



18/22

TGGTGGATGCTAAATTATGATGCTCACCCCTCAGGCTCTGCTGCCCTTTAATCTGGATGAACACACCGAGGACTTTC 4160  
 W W M L I M I L T F Q V S A P P L I W M N T T H D S S  
 G S C F L R S L L P L S G T P P T L L  
 L V D A N Y D P H P S G L L D H H P R L F  
 ACAGGGCCACAGAGGCGAATTGGATACAGTCTCTTACAGCATGTTGGGGTGGACAGCATGCTGAGAGGAAAAACA 4240  
 Q Q H V R P H L D T V S Y S M L G V D S D G R E K  
 H R A T R G R I W I Q C L M G W T A M V K K T  
 T G F F E A E F G Y S V L Q H V G G G Q R W E G K T Q  
 GAGGACCTGGGATCGGACTGCACTCACTGATAAAGGGGAGACCGGTCCAAGCTGGCTTTAAGAGTGGCTGGGG 4320  
 R G P W D R D Y A L T D K G E D R S K L A F E S A W G  
 E D R G I C T H N H S L I K G A T G P S W L K V P G A  
 P T V O S G G L C T H H R Q G P V Q A G L K C L F  
 TCCATGACGGTCTCATGCACTCTCCGTCTCACTACTAAGAGCAGTCTCAGCGGATCTTTATATCCATATCTCCTTCC 4400  
 S M T S H A L S L S L Y V G F C S P F D L V I H I L L P  
 L P R L M H S P S H Y T K D N A M K F F I S I F S F  
 L H D V S C T L F L T I L R T M L T G S L Y P Y S P S  
 AGGATGCTGGTGGCTGCCCTGGGATGGCCATCAGGTGACCGAGAGGGGATGTTATCTGCTCTATAGGGGGATT 4480  
 G C W W V P P G M G H Q V T G E G M F I V A L G D  
 C D A Q Q C P L G W A I R P E R E G C L S L L Y R G I  
 R M L V V P P W D G F S G D B P E R G D V V R C S I G G F  
 CCACAGTCTCATGTACCAAGGCCAGCTGGGTGAAGAAGAGCTGACCTTTGCCCTGCTAATCTCGATGTTGACATC 4560  
 S T V L H V P K A T W V R R S L T F P P L L T P D V D I  
 F O C S M Y Q R P P G E E A P P P C F L M L T I  
 H S A P F C T E G H G K K K P D L S P A H S C H  
 TAGTAAGCTGACCCCTGGAGCTTCTCTCAATGACCTGAACTAAGAAGCGGAAGTATGACCTGACTTCACTT 4640  
 L L P L G P C L Q P T K E A E L P H D F I L  
 L V T L T P W T L S S M T L N R S R T M T P L H S  
 CTTCACCTCTCTCCAGCAGGTGACTATCAAGTGGAAATCTCTCAGCCTCTGTGAATATGCACTAGGAGATGTC 4720  
 F Y P S S N Q V T I N L E I P L S L I C T T G C  
 S L T L P P T R L S T W K F L S A C C E Y A P R D V  
 L Y R R Q L Q F G D Y G L G N S Q P A V N M H L G M S  
 TCTACTAGAGCAGATGCTATGGGGATTCATGCTGAGCTGAAGAAGGGGCTCAGAAAGTTACAGCAGGGGAAGAG 4800  
 L Y R R Q H L M G D S W A E R R A S E G S Q Q G R E  
 E T R D R C W G I H G E L K E G P K V H S R E E S  
 L L E T D A D G G G F M V S K K K O L R K V H S T A G K R  
 CATATGTGATCTGGGCACTGGTGGCTTGGGCTTTATCCAGTGTCTCGAGGAGAGTCTCAGGCGTGATCTACAGAGT 4880  
 H Y G I W A V V A W A F H P S V L E A E S G L I Y R V  
 I M V S G O W W L G P F I D V F W R Q S Q A S T E  
 A L N Y L G S G G L G L S S Q C S G G R V R P D L Q S  
 GAGCTCCAGGACAGCAAGGCTATGACAGAGAAACCGCTTTTGAAGAAACCAAACTAACCAAAACCAAGAAC 4960  
 S S R T A K A M O R N P V L K N P K P K L T Q Q Q Q  
 A A P G Q P R L C R E T L F P E R P S Q A W G M  
 E L Q D S Q G Y A E K P C F E K P K T K T N Q T T T  
 AGAAAAAGCACCGGTGAAGGAATTAGTCTGTATGAAGAGAGCAAGGAATTCAAAACCTAGAGAGCAGGACAGGGT 5040  
 Q K K H R G K G N S V K R O G T I G N P R E Q G R V  
 R K S V V R E S L Y R R D K E F K T L E S S K A G F  
 E F A P P G K K L V C I E E T R S K F A R A Q G  
 CCGATGAGTGGTCTGATCTCTCTTTAACTAGGTGTGTGTTCCGAGAGGCCCTCTCAAGCTCTGGGATGAATATTTC 5120  
 P H G V V S S L L T C V C F R E A L S L G I T I S  
 P H E W S P S L L F L G V C P E R P S Q A W G M  
 S P W S G L H L S F N V C V P R G P L K P G D N Y F  
 TCTATCCACCGAGGCTCTGGCTCTTGGTCTGGTGGCTGGGAGCTCTGTCTCACTCTGGAATATGTCGCCGT 5200  
 P I S T P O L C A P S L V S C L R Q L C L Q F W N M C P  
 S Y F P P R D V P L F Q L V P A T A L S S V L T V P B  
 GTGGATGCTTCATTGAGGCCCGAGGAGGCTGGCACCCACCGCCCAAGCTGAGCCAGTGGAAAGGCCCTGGAAGCTCAG 5280  
 C G G F I O O G P K P G T H R P T A S G A L L E A Q  
 V D A S F R P P Q G S L A P T A R P V S E G P W H L A Q  
 W H L H S G P R E A W H E F P P N S Q W K G P G S S  
 TTCCGATAGGAGCTGGTGGGAAAAAAGTGAAGCAAGACTTGGTGGAGGCTCTGATGGTATGCTCATCTCC 5360  
 P D R A D A G W E K L G Q R L G G S A W L S S F P  
 S Q I G R L G S K M D K D L V E K L H G M P H H S  
 V F R G C W G V G K T T K T M W R V C M A I I I P  
 AAGTGTGCTTCGACAGAGGCTGCTGTTGCTGAAGTATGAGACTCTCTAGGAGAGCTCTCAAGACAGCAGGAT 5440  
 S V L A K E A P V C L I R I Q T P E S L K T P Q  
 Q V C L O K R L L A N L E F R L L R A S R H T Q D  
 K C A C R A G S C L L T D N S D S L G E F Q D T R I

FIGURE 15d

19/22

CTGTTTTCAGCAACTTAAAAACAAACAAACAGCATATCCTGTGCACAGCCTATCCCTCATCCATCAGCTGTCTCCGAT 5520  
 S G F T H L K K K Q S I S C A Q P I F H P S R V L H  
 L V L P F T K Q N K T A Y P V S L S L L T I H H V S I  
 M P Y Q L L K N K T K Q H I L C T A Y P S S I T C P F

ATCTTATTTTGTGGGTCTATAGATGCAAGTGCAGCTCAGTTATGGGTTCTGCCCTCATGCCCTTCATATACCTTTC 5600  
 I L F L W V L M P S Q H S V I G F S P N A F H I L S  
 S Y F C C S Y L C Q V S T Q L L G F L M F L V S I  
 Y L I F V G L I D A K S A I S I S V L F S C L S Y T P

TTATCTACTGCCCTTGGAGATAGTCTTATGTAGCCGAGGCTGCTCTGATCTTGGAAATTTGCTGCCCTCAGCTTCTCA 5680  
 Y L L F F O R S Y V A Q A V L D L G I C L F Q L L  
 L I Y C L L G D S L M F R L S L I L L F A C L S F S  
 L S T A F W E I V L C S F G C P S W N L L A S A S Q

GTCTCAAGTACTGGGATAAGGCATGATGTCTGCCCTGCCCTTTCCTGAACATGCCCTCTGCCCATCTGATAGGCA 5760  
 S L K Y W D N R H A L S A W P L L N M P S V A I G R A  
 V S T G T I G H H C L G L C T C F L M F L V G H  
 S Q V L G A C I V C L A F A E N A L C G H W G

TGAGTCAAAATGCTGCCCTGCCACAGACACACACAAAGTGAAGGTCTCTAAGTGTCCATAGCACAGGAGTAT 5840  
 V V K Y C P P P Q H T K K R K G S L S V P H R V V  
 E S N T A L P H N T H Y N E S E A L V P K S T G  
 M S Q I L P S P T T T T T Q T K V R L S K C S I A G G S

GQTAGCCCTCTCGCTAGTGATATTTCTATTCTTTACTCTGCCCATCTCTCTCTTTCTTGAATTCACACATGGGAGCTG 5920  
 W G L S L V C H I S F F Y S A H L F F L F P H W G P  
 U A I R T C I F H F F R I S S F F D F T H V S I  
 G R P L A S A Y F I L L C P S L L S L I S T L G T W

CGATGATCTCTCTGATTAATTAAGAGAGAATCCCTTTTAAGTCCGCTGATTGCAGGCTCTCCGGGAGCATGTCCCT 6000  
 C I V L S W L R E N S L L S A C I A A S S W D I L F  
 A Y P P G N E R I P F V P A L O R P P G T S P S L  
 H S T F L V I K R E P F F K C L H C S V L L G H S F

TGCTGACTACGCCACCATCTCTCCATGTTTGTGTTCCTACATATGCGCCCTCTCTAGGCTGTCCGACATCATAGT 6080  
 C L N E F T S F H V F C P P S L C P P S L R N I N G  
 A D Y T T P H P S F H H V A P F L L G C O F H T W  
 L L T T P H I L P C F L F F I T M P P F A V P H T W

ATGCTGCTATTGTTTGGATGGTCCAGAGTATCTATCCCTGTGTCAGAGTTCCAGCTTCTCTCGAGGCTGTGTAGGA 6160  
 C A N C F G W L Q Q V Y L S L V R S S D F P S E A G R  
 R V V L V L P H A P T V V S I P D G Q K F E L S F G W S  
 H S L L F L P H A P T V V S I P D G Q K F E L S F G W S

AGACTGTTTCATGATCCGGAGCAGATACAGGTAAAGAAAGATATGTGGATAGGATTTGGAGGGAAGAAAGTAAACATCC 6240  
 K T V H R S G A D T G K R K I C G D M W E R S R N H S  
 L T F I D E P Q I V V R K R V D R I G G K E V N T P  
 D C S S I S R Y R E K D M W I G L E G K K T L

TGGACCTTGATGTAAAGCAGCATGTCCAGCTCTTGATGACACCTGGGACATTGCTCTACAGAACCTCATGCTCAA 6320  
 W T L G C K Q P C P A S H F G T L S S T E L M L K  
 G P L D V S S H V O P L D T L G H C L L O N S C S  
 L D P W M A A M S S L E N T T L W D I V F V R H N Q

GAACTGTGCATTAACTTACCAAAAAGTACAAAAATTCATAATGTGTGAAGTAAGTTATGATGTGTGGGGGGCCAC 6400  
 R C A I N L P F K S H K N F I M F E V S L L C G G G F  
 N T V O L T Y O K V T K I S C L K V D C V G G H  
 E L C N L T K K S Q K F N N V S K F H I V W G A T

ATCTCAGGCTCTCCCTTGTGCTGTGTATGTGCTGGGCAATGCATGCCATGAGCTCAGGTAGACACACCTGTTCACTT 6480  
 H S L L F F A A C S C L G N A C H E L O V R H T C S L  
 T Q D F F P V A W A H S L H A S L L L G Q C M P A S T H L F T  
 L R A S L C C L L L G Q C M P A S T H L F T

CCGCTCTCATGCTGCTGCAAGTTGAGACACCTGTTAGGGGTTCACTTCCCTTTCATCTTTGTGCTCATCTTCTCTAG 6560  
 P L H A A A G W T H L L G V H P P F I L C A P S S L R  
 P D I V V G H T C G F S P S P S F V L H L L H L K  
 S P S S C R L D T V R C G S L P H L F C S I F S T

CTCTCATACATCCCATGTGGGACATGCTATTGTTTCAGGTAGGACTGTCAGACTAGGGAGAGAACCTGTGCTGATG 6640  
 A L H T I S N V G T V S I L S A D W Y S T G R E L C R  
 L I Z I F H M W A H G L L F S G R T G T V R G E P C A

AGTGCTCCCTGGGAGACTCCGAAACAGGAAGAAGTTGTGAGAGCAGCAGGAAGCACTAAGTCGAGCGGAGAGGCGAGA 6720  
 E W S L G D F B T K E E V V B A A R N L S R R E G R E  
 S G P F E T E S Q K K L E Q G G T F V G G K R G R K  
 V P G R L F N K G R S C E R S K E P K S E G R A R

ACGAGAACCCGCAAGGATCATGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 6800  
 T P T A Q A I H V A W D I V K G S C R E G G R I R  
 R E P P K R S W N G E T L L K G V S V R E E G S A  
 H E N R P S D H G G M V R H C K G V V G R R K D Q

FIGURE 15e

GAGAGGAGGAAGGGTCTGGATGTGTATTGATACATCACAGAATGGTCCTGGCGGCTTATCTTTATCTGCATGCCAAGAGTT 6980

E R E R V R V S V T V Y T G Q S D Q L G A Y L Y L H A R S  
G R G R G S G V . C I N H M L M W A L I F I C M P E V  
G E G E G L E C S V Y I T R C S G R L S L S A C Q K F

COTGAGCAAGGCTAGGTTGCTGTCCACATCATCTCTCTACTGATTTGCATTTGATGTGCTCTGGTGCGTATCTCTC 6990

S W R K A R L L S P Y S L L L L V L H F M V S G V S L  
R G G R L G C C H H T L S Y C I C I L W C L W Y L S  
V E E G . V A V T I L S L T V F A F Y G V C G C I S

CTGTGCTCTGCTTCTGCACAGAACCTCATCTTCTCTACTAGTCGTCGTAATCTGATATACTAGCTCTCTAA 7000

L V C S V S A A R R T P S F L F Y S G V N S T . L L N  
L S V L F L H T E L H L S S E T P A S I L I P S F S  
P C L F C F C T Q N S I F P L L L R Q F . Y L A S Q

CCATCGAGCCCTAGTATTCTTCAAACATGATCTAAACCTCTGGGAGAGCTACATGACCTGACTGTCTTATTCCTC 7120

H S R P S T F L K H R D S K P L R L H D L T V F I L  
T T H A L V F F S N M T L N L W G G Y M T . L S L F S  
F L T P . Y S F Q T . L . T S G E A T . P D C L Y S F

A G T T C T G A T C T C A A C C A A G G T T T G C T G A A T G A C T A T A A A A A A A T G C T T G T A C A T T A C A C T A G A 7200

Q F L D L V N P S C . M N L . I N N A C T Y L H .  
. S S L I L S T O V F A E . I Y K . I M L V H I Y T D D  
V P . S C O F K C L L N E S I N K . C L Y I F I T L M

C A G A T T T T T A T A T G T C T G G C A T C T A A A C A G T C A G T T O G A C T C T G S C A G T T G C A T T A G A T A C T T G G G 7280

O I I L Y P F C H L S N Q S V T L C Q A T C A C . I L L G  
R L F Y M F R A I T V K L L C A S A L H A R Y C W T  
D Y V F J I C S V S K S O S C D S P V C M L D T V G

G A A T G T T A G A A A G C T G A C C T A G C T G C A C A G T T A A T A C A C T A T C G G S C A G C G T C G A T C G A A C G T 7360

N G V E D I . P O . T A D S V T L V L H G A C H A Q A  
C M H S L D L S E R L E T V L I H V T S M F A C K P  
E W C R R R H T V S N C . Q C . Y T I R A C L H S L

G T G T A T T G C A T A T G C C A C A C A C A T A T A G C A T A A G C A T C T T T A T C T C T C T T A G C A C A G A A G G T 7440

C V V Y H A Y A R T Y . P A C S I T L S L L A G C A C . I L L G  
C M H S L D L S E R L E T V L I H V T S M F A C K P  
C V C A C I C T H I N M T I . N S F I S A L S L S E E G

T C A G T C A C C C G G G G G A C A C A G A G C C G C A G G C T G A T G T C G A C T A T G A G A G T C C C A T G A G A G A G 7520

S V S P G G G D D Q R P L G C W . I S L M S P M M E R  
O S V P G C T G C T G A C A C A G A G C T G A T G A G A G  
S C C S B G G G T F E A A R L V C V T T D G S E N D G C

F A C C T C A C A G C C T A A A G C C T G A G C T G C A G A T G C A G T T A T G G A T T C G G T G A G A C T T G A T C A A G T C C A 7600

N F C A G R R F V L R A E . H V M G G T T R D L L I K S  
G S S S A K G C C T G A G C C T D L D C E T T G A T G A G  
T L T A A L L K A C E A G G V T R Y G I A V F L T G T G T A T

G T T G T T T T T G T G T A T G C T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T G T 7680

V C F V L C C V I V C V C V C V C V C V C V C V C V . Y  
V V L F C V I S C V C V C V C V C V C V C V C V C V . D  
L A T C F V L Y A R V C V C V C V C V C V C V C V C V . I

G T G T G A C T C A G T C A G C A T A C A T C T G T A T T A T C G G G T C A G A C A A C A C T C A G A T T G T G T C T C A C T T C C A 7760

V C M H O C T Y H S Y M R V R E Q P Q M L V L T F H  
C A C I S A N T I V C I C G S E N N L R C W S S P S  
C T V H S V H I F . C V Y A A G Q R T A T T S D V G P H L F

T T T T C C A A C T G A T A T C T G T C T T G G G A C A T A A G C A A G C T A G C T G A C C A A G A T T T G G C A G G T C T 7840

L F P N W I S C S L R H T I S O I S . P T S L G Q V  
I L V O T G Y L V H F G I Q . A R L A D P O V L G R S  
S C S K L D I L F L T S A Y N K P D . L T H X S W A G L

T C T G T C A G C C T G T C T G T G T G A G A C G T T G G A A T T A C A G A T A A G C T G A T A C G A A T C T G C A G C C G G 7920

F L S V L L S L L G L R H S G I Y R . A . Y R I P A A R  
S V S A S C L L V . G I L E F T D K L D I E F L O P G  
L S O P P V S W F E A F A N N L Q I S L I S N S C S P

OGAATCCACTNTTCTAGAGAGCGCCGCCACCAAGGAG 7958

G I H F . S . S G R H Q G S  
G S T S S R A A A T K G  
G S P F . S . S G R H Q G S

SUBSTITUTE SHEET (RULE 26)

21/22

1 2 3 4

20  
15  
10  
5  
0  
-5  
-10  
-15  
-20  
-25  
-30  
-35  
-40  
-45  
-50  
-55  
-60  
-65  
-70  
-75  
-80  
-85  
-90  
-95  
-100



FIGURE 16

22/22




FIGURE 17

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY**  
(Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

003300-685

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**An integrin heterodimer and a subunit thereof**

the specification of which (check only one item below):

☐ is attached hereto.

☒ was filed as United States application

Number \_\_\_\_\_

on **2 October 2000**

and was amended

on \_\_\_\_\_ (if applicable).

☐ was filed as PCT international application

Number \_\_\_\_\_

on \_\_\_\_\_

and was amended

on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

**PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119:**

| COUNTRY<br>(if PCT, indicate "PCT") | APPLICATION NUMBER | DATE OF FILING<br>(day, month, year) | PRIORITY CLAIMED<br>UNDER 35 U.S.C. §119                            |
|-------------------------------------|--------------------|--------------------------------------|---------------------------------------------------------------------|
| Sweden                              | 9801164-6          | 2 April 1998                         | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Sweden                              | 9900319-6          | 28 January 1999                      | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
|                                     |                    |                                      | <input type="checkbox"/> Yes <input type="checkbox"/> No            |
|                                     |                    |                                      | <input type="checkbox"/> Yes <input type="checkbox"/> No            |

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

\_\_\_\_\_  
(Application Number)

\_\_\_\_\_  
(Filing Date)

**COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED)**  
(Includes Reference to Provisional and PCT International Applications)

Attorney's Docket No.

003300-685

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations §1.56, which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

| U.S. APPLICATIONS                     |                  | STATUS (check one)                         |         |           |
|---------------------------------------|------------------|--------------------------------------------|---------|-----------|
| U.S. APPLICATION NUMBER               | U.S. FILING DATE | PATENTED                                   | PENDING | ABANDONED |
|                                       |                  |                                            |         |           |
|                                       |                  |                                            |         |           |
| PCT APPLICATIONS DESIGNATING THE U.S. |                  |                                            |         |           |
| PCT APPLICATION NO.                   | PCT FILING DATE  | U.S. APPLICATION NUMBERS ASSIGNED (if any) |         |           |
| PCT/SE99/00544                        | 31 March 1999    |                                            |         |           |
|                                       |                  |                                            |         |           |

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

|                           |        |                      |        |                        |        |
|---------------------------|--------|----------------------|--------|------------------------|--------|
| William L. Mathis         | 17,337 | R. Danny Huntington  | 27,903 | Gerald F. Swiss        | 30,113 |
| Robert S. Swecker         | 19,885 | Eric H. Weisblatt    | 30,505 | Michael J. Ure         | 33,089 |
| Platon N. Mandros         | 22,124 | James W. Peterson    | 26,057 | Charles F. Wieland III | 33,096 |
| Benton S. Duffett, Jr.    | 22,030 | Teresa Stanek Rea    | 30,427 | Bruce T. Wieder        | 33,815 |
| Norman H. Stepno          | 22,716 | Robert E. Krebs      | 25,885 | Todd R. Walters        | 34,040 |
| Ronald L. Grudziecki      | 24,920 | William C. Rowland   | 30,888 | Ronni S. Jillions      | 31,979 |
| Frederick G. Michaud, Jr. | 26,003 | T. Gene Dillahunty   | 25,423 | Harold R. Brown III    | 36,341 |
| Alan E. Kopecki           | 25,813 | Patrick C. Keane     | 32,858 | Allen R. Baum          | 36,086 |
| Regis E. Sluter           | 26,992 | Bruce J. Boggs, Jr.  | 32,344 | Steven M. du Bois      | 35,023 |
| Samuel C. Miller, III     | 27,360 | William H. Benz      | 25,952 | Brian P. O'Shaughnessy | 32,747 |
| Robert G. Mukai           | 28,531 | Peter K. Skiff       | 31,917 |                        |        |
| George A. Hovanec, Jr.    | 28,223 | Richard J. McGrath   | 29,195 |                        |        |
| James A. LaBarre          | 28,693 | Matthew L. Schneider | 32,313 |                        |        |
| E. Joseph Gess            | 28,510 | Michael G. Savage    | 32,596 |                        |        |



21839

and: None

Address all correspondence to:



21839

Benton S. Duffett, Jr.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: Benton S. Duffett, Jr. at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-2  
COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONTINUED)  
(Includes Reference to Provisional and PCT International Applications)

ATTORNEY'S DOCKET NO.

003300-685

FULL NAME OF SOLE OR FIRST INVENTOR

**Evy Lundgren-Akerlund**

SIGNATURE

*Evy Lundgren-Akerlund*

DATE

2000-10-09

RESIDENCE

**Bjärred, Sweden** *SEX*

CITIZENSHIP

**Sweden**

POST OFFICE ADDRESS

**Trollsjövägen 165, 237 33 Bjärred, Sweden**

FULL NAME OF SECOND JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF THIRD JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF FOURTH JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF FIFTH JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF SIXTH JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF EIGHTH JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS

FULL NAME OF NINTH JOINT INVENTOR, IF ANY

SIGNATURE

DATE

RESIDENCE

CITIZENSHIP

POST OFFICE ADDRESS